

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Acid-fast characteristics,

- Infection by *Mycobacterium haemophilum*, a metabolically fastidious acid-fast bacillus.
Mouldale, M. T., *et al.* (A) 301
Ultrastructure of *Mycobacterium leprae* and other acid-fast bacteria as influenced by
fixation conditions. Silva, M. T. and Macedo, P. M. (A) 448

Acid, fatty,

- Fatty acid and polar lipid analysis as tools in the identification of *Mycobacterium leprae*
and some related slow-growing mycobacterial species. Anderson, O., *et al.* (A) 445
Gas chromatography of constitutive fatty acids in *Mycobacterium leprae*. Kusaka, T.
and Izumi, S. (A) 624

Actinomycete(s),

- Crossreactivity between *Mycobacterium leprae* and various actinomycetes and related
organisms. RIDELL, M. (O) 185
Growth of actinomycetals in relation to the pH of the medium. Portaels, F. and Ki-
manuka, T. (A) 634

Adenosine triphosphatase (ATP),

- Application of ATP assays to patient care in leprosy. Dhople, A. M. (A) 653
Reduction of potassium tellurite and ATP content in *Mycobacterium leprae*. David, H.
L., *et al.* (A) 445

Africa,

- Experimental transmission of leprosy in African green monkeys (*Cercopithecus aethiops*)
and the rhesus monkey (*Macaca mulatta*). Wolf, R. H., *et al.* (A) 664
Leprosy in Zimbabwe. Lyons, N. F. and Ellis, B. P. B. (A) 296
Leprosy under control in Togo with work done increasingly by Togolese. (N) 595
Remarks on the orofacial symptoms of leprosy observed in Somalia. Goracci, G. and
Clangelo, G. (A) 614
Southern Sudan to receive DM1.8 million for leprosy work from the German Leprosy
Relief Association. (N) 595
Zimbabwe Leprosy Symposium. Browne, S. G. (N) 596

Allergy,

- Dissociation between allergy and immunity in mycobacterial infections. Turk, J. L. ... (A) 288

Alpha-1-antitrypsin,

- Alpha-1-antitrypsin in lepra reaction. Chawhan, R. N., *et al.* (A) 614

American Leprosy Missions (ALM),

- Dr. Roy F. Pfaltzgraff joins American Leprosy Missions. (N) 124

Amikacin,

- Activity of amikacin against mycobacteria *in vitro* and in murine tuberculosis. Sanders,
W. E., Jr., *et al.* (A) 156
Amikacin in the treatment of pulmonary tuberculosis. Allen, B. W., *et al.* (A) 63

Anemia,

- Hemolytic anemia induced by dapsone transmitted through breast milk. Sanders, S. W.,
et al. (A) 275

Antibody(ies),

- Definition of species-specific and cross-reactive antigenic determinants of *Mycobacte-
rium leprae* using monoclonal antibodies. Ivanyi, J., *et al.* (A) 619
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies
to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan,
T. M. (A) 660

- Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* (A) 300
- Effect of treatment on antibody activity against *Mycobacterium leprae* antigen 7 in tuberculoid leprosy. DAHLE, J. S., *et al.* (O) 312
- Evaluation of the significance of antibodies to phenolic glycolipid of *Mycobacterium leprae* in leprosy patients and their contacts. Buchanan, T. M., *et al.* (A) 658
- Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* (A) 655
- Generation and characterization of monoclonal antibodies to the *Mycobacterium leprae* phenolic glycolipid. Khanolkar, S. R., *et al.* (A) 662
- High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* (A) 138
- IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* (A) 136
- Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., *et al.* (O) 33
- Laboratory diagnosis of tuberculous lymphadenitis using soluble antigen fluorescent antibody test. Kiran, U., *et al.* (A) 155
- Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., *et al.* (A) 442
- Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., *et al.* (O) 305
- Salivary immunoglobulin and antibody activities in leprosy. Abe, M., *et al.* (A) 657
- SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* (A) 134
- Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shrinivas. (A) 154
- Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-related antigen in syphilis and leprosy. Morito, T., *et al.* (A) 619
- T cell subsets in leprosy lesions: *in situ* characterization using monoclonal antibodies. Narayanan, R. B., *et al.* (A) 287
- The production of human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T. and Roder, J. C. (A) 656
- The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* (A) 621
- Antigen(s),**
- Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* (A) 156
- Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. (A) 299
- Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., *et al.* (A) 623
- Definition of species-specific and cross-reactive antigenic determinants of *Mycobacterium leprae* using monoclonal antibodies. Ivanyi, J., *et al.* (A) 619
- Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* (A) 155
- Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* (A) 443
- Effect of treatment on antibody activity against *Mycobacterium leprae* antigen in tuberculoid leprosy. DAHLE, J. S., *et al.* (O) 312
- Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* (O) 481
- Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae*. Hunter, S. W. and Brennan, P. J. (A) 623
- Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* (A) 655
- Hepatitis-B-surface antigen (HBsAg) in leprosy patients. Balakrishnan, S., *et al.* (A) 439

HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. Xu Keyu, <i>et al.</i> (A)	150
HLA antigens in leprosy patients. Bale, U. M., <i>et al.</i> (A)	146
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., <i>et al.</i> (A)	442
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., <i>et al.</i> (O)	33
Immune-response gene-associated antigens (Ia/DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. (A)	632
<i>In vitro</i> induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. (A)	443
Laboratory diagnosis of tuberculous lymphadenitis using soluble antigen fluorescent antibody test. Kiran, U., <i>et al.</i> (A)	155
Prevalence of Australia antigen (HBsAg) in hanseniasis patients. Sarno, E. N., <i>et al.</i> . . . (A)	281
Ribosomal antigens of <i>Mycobacterium leprae</i> . Ridell, M. (A)	291
SDS-PAGE analysis of <i>M. leprae</i> protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., <i>et al.</i> (A)	134
Sensitization or tolerance to <i>Mycobacterium leprae</i> antigen by route of injection. Shepard, C. C., <i>et al.</i> (A)	138
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A)	157
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shrinivas (A)	154
Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-related antigen in syphilis and leprosy. Morito, T., <i>et al.</i> (A)	619
Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., <i>et al.</i> (A)	283
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., <i>et al.</i> (A)	133
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. (A)	137
Argentina,	
1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky, C. B. (A)	151
Infantile leprosy in the registry of patients of the Service of Leprology of the Policlinico Intendente Carrasco de Rosario. Arpini, R., <i>et al.</i> (A)	451
Registry of patients of the Service of Dermatoleprology of the Policlinico Intendente Carrasco de Rosario. Arpini, R. H., <i>et al.</i> (A)	451
Sociedad Argentina de Dermatologia (Asociacion Medica Argentina). (N)	596
Armadillo(s),	
A new communication on natural mycobacteriosis in armadillos (<i>Dasypus novemcinctus</i> Linn.). Martinez, A. R., <i>et al.</i> (A)	144
A single subcutaneous inoculation of 10 ⁷ armadillo-derived irradiated <i>Mycobacterium leprae</i> evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., <i>et al.</i> (A)	450
Bacteriological studies of armadillo livers infected with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	141
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in <i>Mycobacterium leprae</i> grown in armadillo tissues. Wheeler, P. R. (A)	624
Disposition of prothionamide in rats and armadillos. PETERS, J. H., <i>et al.</i> (O)	54
Leprosy in wild armadillos (<i>Dasypus novemcinctus</i>) of the Texas Gulf Coast: Epidemiology and mycobacteriology. Smith, J. H., <i>et al.</i> (A)	629
Progress in the preparation of an antileprosy vaccine from armadillo-derived <i>Mycobacterium leprae</i> . REES, R. J. W. (O)	515
SDS-PAGE analysis of <i>M. leprae</i> protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., <i>et al.</i> (A)	134

- Sylvatic leprosy in wild armadillos of the Texas Gulf Coast. Smith, J. H., *et al.* (A) 663
- The mycolic acids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Draper, P., *et al.* (A) 446
- Variable lepromin response to *Mycobacterium leprae* in resistant armadillos. Job, C. K., *et al.* (O) 347
- Arthropod(s),**
- Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. (A) 628
- Asia,**
- A study of case-holding in leprosy patients in Asia, based on duration of treatment. Collier, P. J. (A) 627
- Leprosy; our Southeast Asian refugee experience. Younger, B., *et al.* (A) 150
- Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia, Bangkok, Thailand, 18–28 January 1982. (B) 607
- Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. (B) 608
- Assay(s) (see also ELISA),**
- Application of ATP assays to patient care in leprosy. Dhople, A. M. (A) 653
- Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. (A) 660
- Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* (A) 443
- Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A) 157
- Australia,**
- Leprosy in the Northern Territory of Australia with Particular Reference to the Aborigines of Arnhem Land and the Arid Regions of the Northern Territory.* Hargrave, J. C. (B) 433
- Baby(ies),**
- A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., *et al.* (O) 7
- IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* (A) 136
- Bacilli,**
- A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., *et al.* (A) 280
- Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* (A) 288
- Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. HIRATA, T. (O) 84
- Induction of delayed type hypersensitivity against ultrasonicated *Mycobacterium lepraemurium* bacilli without simultaneous local reactivity against live bacilli. Løvik, M. and Closs, O. (A) 625
- Infection by *Mycobacterium haemophilum*, a metabolically fastidious acid-fast bacillus. Moulds, M. T., *et al.* (A) 301
- Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guerin. Edwards, M. L., *et al.* (A) 453
- Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. (A) 628
- Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* (O) 466
- The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection,

linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., <i>et al.</i> (A)	302
The <i>in vitro</i> culture of the leprosy bacillus. BAKER, C. J. (E)	397
Bacteriology,	
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. (A)	131
Bacteriological studies of armadillo livers infected with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	141
Bacteriology of <i>Mycobacterium leprae</i> . Pattyn, S. R. (A)	624
Bacteriophage typing of strains of <i>Mycobacterium tuberculosis</i> from Nepal. Goode, D. (A)	299
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., <i>et al.</i> (A)	279
Leprosy review: The bacteriology of <i>Mycobacterium leprae</i> . DRAPER, P. (O)	563
Morphology of bacteriophages from <i>Mycobacterium lepraemurium</i> . Rastogi, N. and David, H. L. (A)	142
<i>Mycobacterium leprae</i> infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., <i>et al.</i> (A)	293
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. (A)	438
BCG (bacille Calmette-Guérin),	
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., <i>et al.</i> (A)	302
Antigens of PPD, old tuberculin, and autoclaved <i>Mycobacterium bovis</i> BCG studied by crossed immunoelectrophoresis. Harboe, M. (A)	299
Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., <i>et al.</i> (A)	301
Changes in BCG strains. Osborn, T. W. (A)	301
Comparative immunogenicity of BCG and <i>Mycobacterium leprae</i> in normal and in <i>M. leprae</i> -tolerant mice. Shepard, C. C. (A)	646
Comparison of the immunogenicity of vaccines prepared from viable <i>Mycobacterium bovis</i> BCG, heat-killed <i>Mycobacterium leprae</i> , and a mixture of the two for normal and <i>M. leprae</i> -tolerant mice. Shepard, C. C., <i>et al.</i> (A)	626
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., <i>et al.</i> (A)	300
Effect of purified protein derivative and sonicates of <i>Mycobacterium leprae</i> and <i>Mycobacterium bovis</i> BCG on thromboplastin response in human monocytes. Lyberg, T., <i>et al.</i> (A)	285
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)	294
IgE in leprosy; effect of a <i>Mycobacterium leprae</i> -BCG vaccine. LYNCH, N. R., <i>et al.</i> (O)	169
<i>In vitro</i> induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. (A)	443
Infection with <i>Mycobacterium avium-intracellulare</i> and the protective effects of bacille Calmette-Guérin. Edwards, M. L., <i>et al.</i> (A)	453
Intradermal BCG vaccination complications—analysis of 51 cases. Murzy de Souza, G. R., <i>et al.</i> (A)	301
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. (A)	621
Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. (A)	622
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. (A)	139
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. (A)	296

The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., <i>et al.</i> (A)	621
The use of subcellular components of BCG for studying host-mycobacterium interaction in relation to leprosy. Das, P. K., <i>et al.</i> (A)	282
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., <i>et al.</i> (A)	301
Behçet's Syndrome,	
Abnormalities of T-cell subsets in Behçet's syndrome. Soo Duk Lim, <i>et al.</i> (A)	302
Belehu, Ayele,	
Obituary. Haregewoin, A. and Olcen, P. (Ob)	404
Belgium,	
Prix des Concours Ordinaires awarded Madame Françoise Antoine-Portaels. (N)	596
Biochemistry,	
Biochemical studies of leprosy-derived corynebacteria. Cocito, C., <i>et al.</i> (A)	140
Biochemical investigation of the peribacillary substance of <i>Mycobacterium leprae</i> . Fukunishi, Y., <i>et al.</i> (A)	668
Biochemical properties of <i>Mycobacterium lepraemurium</i> cultivated in cell-free liquid medium. Nakamura, M. (A)	654
Blood,	
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., <i>et al.</i> (A)	649
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W. (A)	283
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., <i>et al.</i> (A)	133
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., <i>et al.</i> (A)	647
Bolivia,	
Epidemiologic patterns of leprosy in Vallegrande, Bolivia. De Muynck, A. (A)	295
Bone,	
An unusual location of leproma of bone; a case report. ANDERSEN, J. G. and WARN-DORFF, J. (O)	203
Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., <i>et al.</i> (A)	630
The rate of loss of maxillary anterior alveolar bone height in patients with leprosy. Subramaniam, K., <i>et al.</i> (A)	615
The resistance of C57BL/6 mice to subcutaneous infection with <i>Mycobacterium lepraemurium</i> is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., <i>et al.</i> (A)	625
Borderline leprosy,	
A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., <i>et al.</i> (A)	280
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. (A)	131
Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., <i>et al.</i> (A)	285
Leprosy, borderline-lepromatous, and cytomegalovirus infection. Kruyt, J. A., <i>et al.</i> (A)	278
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., <i>et al.</i> (A)	613
Orchiepididymitis in dimorphous leprosy. Gimenez, M. F. and Tonelli, H. B. (A)	278
Positioning of borderline and indetermined groups in the hanseniasis classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. (A)	128
Relation between anti- <i>Mycobacterium leprae</i> antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., <i>et al.</i> (O)	305

Bowel,

- Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. BELAUBE, P., *et al.* (O) 328

Brazil,

- Epidemiology of hanseniasis in the state of Rio Grande do Sul. Bernardi, C. and Ferreira, J. (A) 146
 II International Congress of the College of Hansenology of the Endemic Countries. (N) 263
 IV Brazilian Congress of Hansenology. Bechelli, L. M. (N) 118
 Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. 1. General characteristics. Asseis, E. A., *et al.* (A) 145
 Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. 2. Specific characteristics. Tornero, N., *et al.* (A) 297
 The epidemiology of leprosy in Chaco. Risso, H. I. (A) 296

Burma,

- Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18-19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. (O) 500

C3,

- A single subcutaneous inoculation of 10⁷ armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* (A) 450
 An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* (A) 138
 CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* (A) 618
 Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Hari-krishnan, S., *et al.* (A) 134
 Serum levels of C3-activator (antifactor B) in leprosy. WEMAMBU, S. N. C. (C) 259
 Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* (A) 625
 Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* (A) 144

C3d,

- An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* (A) 138

Cancer,

- Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia, and lepromatous leprosy. Moura, N. C., *et al.* (A) 443

Candida albicans,

- Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* (A) 283
 Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* (A) 287

Candida pseudotropicalis,

- Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* (A) 283

Carbon,

- Metabolism of carbon sources of *Mycobacterium leprae*: a preliminary report. Wheeler, P. R. (A) 143

Caribbean,

- III Meeting of the Standing Committee of Leprosy Control in the Caribbean (SLCC III). (N) 120

Cat(s),

- Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schieffer, H. B. and Middleton, D. M. (A) 626

Catalase,

- Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* (A) 290
- Serological approaches for the characterization of catalase in tissue-derived mycobacteria. Katoch, V. M., *et al.* (A) 624

Cell(s),

- Abnormalities of T-cell subsets in Behçet's syndrome. Soo Duk Lim, *et al.* (A) 302
- Activated suppressor T cells in leprosy. Mehra, V., *et al.* (A) 136
- Binding of phosphatidylethanolamine and phosphatidylinositol to OKT8+ lymphocytes activates suppressor cell activity. Wadee, A. A. and Rabson, A. R. (A) 445
- Biochemical properties of *Mycobacterium lepraemurium* cultivated in cell-free liquid medium. Nakamura, M. (A) 654
- Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* (A) 301
- Characterization of a suppressor cell-activating factor (SCAF) released by adherent cells treated with *M. tuberculosis*. Wadee, A. A., *et al.* (A) 444
- Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* (A) 290
- Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., *et al.* (A) 139
- ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., *et al.* (O) 321
- Defect in the generation of cytotoxic T cells in lepromatous leprosy. Stach, J.-L., *et al.* (A) 444
- Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in *Mycobacterium lepraemurium* infection. Hoffenbach, A., *et al.* (A) 292
- E-rosettes in leprosy patients. Manimakalai, *et al.* (A) 285
- Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., *et al.* (A) 156
- Effects of vaccination with *Mycobacterium leprae* on local cell-mediated immunity. Ridet, P.-R., *et al.* (A) 645
- Enhanced growth of *Mycobacterium lepraemurium* in cell-free liquid medium with DL-aspartic acid. Nakamura, M. (A) 290
- Evidence for generation of suppressor T cells in *Mycobacterium lepraemurium*-infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hirooka, Y. (A) 450
- Growth stimulation of *Mycobacterium lepraemurium* by liposome in cell-free liquid medium. Nakamura, M. (A) 141
- Identification of T-cell subpopulations in granuloma annulare. Buechner, S. A., *et al.* (A) 298
- In vitro* induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. (A) 443
- In vitro* proliferative response to *M. leprae* and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., *et al.* (A) 442
- Increased helper-suppressor T cell ratio in psoriasis. Ligesti, D. J., *et al.* (A) 155
- Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. (A) 274
- Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. (A) 621
- Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. (A) 622
- Langerhans' cell and leprosy. Mathur, N. K., *et al.* (A) 443
- Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. (A) 628

Leprosy XII. T-cell subsets in lepromatous leprosy. Lim, S. D., <i>et al.</i> (A)	443
Mechanisms of T-cell unresponsiveness in leprosy. Bach, M.-A., <i>et al.</i> (A)	616
Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., <i>et al.</i> (A)	442
Rosette-forming cells in patients with treated leprosy. DANG DUC TRACH, <i>et al.</i> (O)	174
Serum-mediated suppression of E-RFC levels in leprosy and reversal by fetal calf serum. Jaswaney, V. L., <i>et al.</i> (A)	284
Stimulating effects of lecithin and cholesterol on the growth of <i>Mycobacterium lepraemurium</i> in cell-free liquid medium. Nakamura, M. (A)	141
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., <i>et al.</i> (A)	649
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tubercu- loid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., <i>et al.</i> (A)	650
Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., <i>et al.</i> (A)	134
Suppressor cells of mouse and man. What is the evidence that they contribute to the aetiology of the mycobacterioses? Rook, G. A. W. (A)	137
T cell subsets in leprosy lesions: <i>in situ</i> characterization using monoclonal antibodies. Narayanan, R. B., <i>et al.</i> (A)	287
T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Har- gewoin, A., <i>et al.</i> (A)	618
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., <i>et al.</i> (A)	632
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W. (A)	283
The cutaneous infiltrates of leprosy. Cellular characteristics and the predominant T cell phenotypes. Van Voorhis, W. C., <i>et al.</i> (A)	288
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. (O)	225
The resistance of C57BL/6 mice to subcutaneous infection with <i>Mycobacterium lepraemurium</i> is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., <i>et al.</i> (A)	625
Use of cycloheximide for cultivating <i>Mycobacterium lepraemurium</i> in cell culture. MATSUO, Y. (O)	72
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., <i>et al.</i> (A)	301
CH50,	
CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., <i>et al.</i> (A)	618
Chemotherapy,	
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., <i>et al.</i> (C)	592
Chemotherapy of non-lepromatous leprosy. (A)	609
Leprosy and its chemotherapy. Beeching, N. J. and Ellis, C. J. (A)	129
Nude mice as a model for chemotherapy of leprosy. Kohsaka, K., <i>et al.</i> (A)	437
Polychemotherapy in leprosy. Terencio de las Aguas, J. (A)	612
Report of the 11th and 12th meetings of the Steering Committee of the Scientific Working Group on the Chemotherapy of Leprosy. (N)	429
The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. (A)	613
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., <i>et al.</i> (A)	286
Child(ren),	
Lepromatous leprosy in children. (An account of the last three observations.) Ravettini, B. A., <i>et al.</i> (A)	614

- Leprosy in 18-month-old children, Bichena District, Gojjam Administrative Region, Ethiopia. Fekete, E. and Tedla, T. (A) 295
- Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. (A) 296
- Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., *et al.* (A) 301
- China, People's Republic of,**
- HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. Xu Keyu, *et al.* (A) 150
- National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. Wu Qin-xue. (N) 119
- Second Plenary Session of the National Consultative Committee on Leprosy Control convened at Kunming. Ye Gan-yun. (N) 266
- Workshop on Epidemiology and Statistics in Leprosy held in Guangdong. Ye Gan-yun. (N) 430
- Chloramphenicol,**
- Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with thalidomide. Saint-André, P., *et al.* (A) 611
- Cholesterol,**
- Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae*. Kurup, I. G. and Mahadevan, P. R. (A) 135
- Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium leprae-murium* in cell-free liquid medium. Nakamura, M. (A) 141
- Chromatography,**
- Gas chromatography of constitutive fatty acids in *Mycobacterium leprae*. Kusaka, T. and Izumi, S. (A) 624
- Classification of leprosy,**
- Analysis of the inter- and intrapathological concordances and discordances in a comparative study of Madrid and Ridley-Jopling classifications of leprosy. Haddad, N., *et al.* (A) 435
- Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., *et al.* (A) 435
- Leprosy classification for use in control programs. Bernardi, C., *et al.* (A) 275
- Positioning of borderline and indetermined groups in the hanseniasis classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. (A) 128
- The Biology of Mycobacteria*. Vol. 1. Physiology, Identification and Classification. Ratledge, C. and Stanford, J., eds. (B) 127
- Clinical,**
- A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., *et al.* (O) 7
- Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., *et al.* (A) 617
- Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., *et al.* (A) 278
- Clinical, electrophysiological and teased fibre study of peripheral nerves in leprosy. Chopra, J. S., *et al.* (A) 631
- Clinical epidemiology of nonlepromatous leprosy among service personnel. (Armed Forces—India). Guha, P. K. (A) 149
- Clinical observation on iridocyclitis in leprosy patients. Acharya, B. P. (A) 612
- Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., *et al.* (A) 435
- Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* (A) 279
- Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., *et al.* (A) 439
- Management of clinical trials in developing countries. de Maar, E. W. J., *et al.* (A) 277
- Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* (A) 630

Relation between anti- <i>Mycobacterium leprae</i> antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., <i>et al.</i> (O)	305
Study of immunological parameters in patients with different clinical forms of leprosy; the influence of treatment. Bottasso, O. A., <i>et al.</i> (A)	133
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., <i>et al.</i> (A)	302
Clofazimine,	
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapson, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., <i>et al.</i> (C)	592
Exudative enteropathy due to clofazimine: about a case. Belaube, P., <i>et al.</i> (A)	129
Reduced estrogen excretion due to clofazimine? DUNCAN, M. E. and OAKEY, R. E. (C)	112
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene*) in the treatment of prurigo nodularis. BELAUBE, P., <i>et al.</i> (O)	328
Cloning,	
Construction and partial characterization of <i>Mycobacterium leprae</i> genomic libraries using an <i>in vivo</i> cosmid cloning system. Jacobs, W. R., <i>et al.</i> (A)	667
Complement,	
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., <i>et al.</i> (A)	138
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., <i>et al.</i> (A)	288
CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., <i>et al.</i> (A)	618
Concanavalin A,	
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., <i>et al.</i> (O)	321
Control of leprosy,	
A 20-year study of the leprosy control programme at the Government Leprosy Treatment and Study Centre at Tirukoilur in South India. Radhakrishna, S., <i>et al.</i> (A)	149
Action plans for leprosy control meeting. (India). Sansarricq, H. (N)	263
An appraisal of medical research in the treatment and control of leprosy. Rees, R. J. W. (A)	271
<i>Basic Epidemiological Indicators for Monitoring Leprosy Control.</i> Lechat, M. F. and Vanderveken, M. (B)	434
Considerations in a leprosy control program. Risso, H. I. and Gimenez, M. M. (A)	150
HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., <i>et al.</i> (A)	150
III Meeting of the Standing Committee of Leprosy Control in the Caribbean (SLCC III). (N)	120
Leprosy classification for use in control programs. Bernardi, C., <i>et al.</i> (A)	275
Leprosy control project funded. (West Indies). (N)	432
Leprosy under control in Togo with work done increasingly by Togolese. (N)	595
Mouse foot pad technique for evaluation of drug resistance of <i>M. leprae</i> and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. (A)	436
Policy and strategy for leprosy control programs. (Latin America). Romero, A. (A)	628
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7-11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. (B)	608
Recent changes in leprosy control. Sansarricq, H. (A)	628
Second Plenary Session of the National Consultative Committee on Leprosy Control convened at Kunming. (China). Ye Gan-yun. (N)	266
Tuberculosis and leprosy control: WHO consultation. (A)	451
Corticosteroid(s),	
Corticosteroids and lepromin sensitivity. Kundu, S. K., <i>et al.</i> (A)	131

Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., <i>et al.</i> (A)	156
Corynebacteria,	
Biochemical studies of leprosy-derived corynebacteria. Cocito, C., <i>et al.</i> (A)	140
Biological properties of diphtheroid bacteria (LDC) isolated from human leprosy lesions. Delville, J., <i>et al.</i> (A)	140
Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., <i>et al.</i> (A)	139
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., <i>et al.</i> (A)	623
Modification of the kinetics of growth of <i>Mycobacterium leprae</i> by a group of corynebacteria. Delville, J., <i>et al.</i> (A)	290
Structure of the wall polysaccharide isolated from a group of corynebacteria. Abou-Zeid, C., <i>et al.</i> (A)	622
Cultivation,	
Pathogenicity of <i>in vitro</i> cultivated <i>Mycobacterium lepraemurium</i> in rats. Ishaque, M. . (A)	293
<i>In vitro</i> cultivation of <i>Mycobacterium X</i> from <i>Mycobacterium leprae</i> -infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. (O)	77
Use of cycloheximide for cultivating <i>Mycobacterium lepraemurium</i> in cell culture. MATSUO, Y. (O)	72
Observations on the host reaction to the cultivated <i>Mycobacterium lepraemurium</i> in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. (A)	294
Biochemical properties of <i>Mycobacterium lepraemurium</i> cultivated in cell-free liquid medium. Nakamura, M. (A)	654
Method of cultivation of <i>M. leprae</i> . Veeraraghavan, N. (A)	291
Cutaneous,	
Assessment of cutaneous autonomic nerve functions in leprosy. Boyle, A. and Ramu, G. (A)	151
Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. (A)	632
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., <i>et al.</i> (A)	650
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., <i>et al.</i> (A)	632
The cutaneous infiltrates of leprosy. Cellular characteristics and the predominant T cell phenotypes. Van Voorhis, W. C., <i>et al.</i> (A)	288
Ulcerative cutaneous mycobacteriosis. Lavalle, P., <i>et al.</i> (A)	633
Cycloheximide,	
Use of cycloheximide for cultivating <i>Mycobacterium lepraemurium</i> in cell culture. MATSUO, Y. (O)	72
Damien-Dutton Society,	
Damien-Dutton Society history. Crouch, H. E. (N)	124
Dr. Ma Haide receives the 1982 Damien-Dutton Award. Lechat, M. F. (N)	422
Dapsone (DDS),	
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., <i>et al.</i> (C)	592
Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. PETTIT, J. H. S. (C)	258
Dapsone compliance in an urban field project. Revankar, C. R., <i>et al.</i> (A)	438
Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. (A)	633
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., <i>et al.</i> (O)	191
Dapsone-resistant leprosy. Pearson, J. M. H. (A)	611
DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk,	

South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., <i>et al.</i> (O)	366
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., <i>et al.</i> (O)	382
Further results on dapsone-resistant leprosy in Bamako (Mali). Baquillon, G., <i>et al.</i> (A)	273
Hemolytic anemia induced by dapsone transmitted through breast milk. Sanders, S. W., <i>et al.</i> (A)	275
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., <i>et al.</i> (O)	461
Monitoring the regularity of self administration of dapsone by leprosy patients. Kumar, A. and Balakrishnan, S. (A)	274
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China) Wu Qin-xue. (N)	119
Qualitative quick simplified methods in the determination of urinary DDS. Jin Liang-Jian. (A)	273
Resistance of <i>Mycobacterium leprae</i> to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., <i>et al.</i> (A)	610
Response to dapsone (DDS) monotherapy in leprosy patients of Gudiyatham Taluk, South India: Comparison between the 1960s and the 1970s. ALMEIDA, J. G., <i>et al.</i> (O)	378
Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., <i>et al.</i> (O)	385
Sensitivity of mycobacteria to dapsone. Portaels, F., <i>et al.</i> (A)	142
Sex differences in the absorption of dapsone after intramuscular injection. MODDERMAN, E. S. M., <i>et al.</i> (O)	359
Social and personality factors in dapsone resistant patients. John, J. K., <i>et al.</i> (A)	437
The significance of dapsone (DDS)-resistant <i>Mycobacterium leprae</i> in untreated patients. ALMEIDA, J. G., <i>et al.</i> (O)	374
Davey, Thomas Frank, Obituary. Seal, K. S. (Ob)	405
Deformity(ies), A study of leprosy patients with deformities and the implications of the treatment of all leprosy patients. Price, J. A. (A)	631
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. (A)	297
Rehabilitation of leprosy deformity. Enna, C. D. (A)	152
Deoxyfructose, Deoxyfructo-serotonin: a new drug with anti-leprosy activity. Mester de Parajd, L., <i>et al.</i> (A)	274
Dermatoglyphics, A preliminary study of dermatoglyphics in patients with leprosy. Ruan Xi-Yuan, <i>et al.</i> (A)	280
A study of palmar dermatoglyphics in leprosy. Nagar, K. S., <i>et al.</i> (A)	279
Dermatology, Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, R. and Grange, J. M. (A)	300
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China) Wu, Qin-xue. (N)	119
Registry of patients of the Service of Dermatoleprology of the Policlinico Intendente Carrasco de Rosario. (Argentina). Arpini, R. H., <i>et al.</i> (A)	451
Sociedad Argentina de Dermatologia (Asociacion Medica Argentina). (N)	596
V International Congress of Tropical Dermatology to meet in Mexico City. (N)	266
Diabetes, Diabetes and leprosy. Terencio de las Aguas, J. (A)	133

Diacylphthiocerol,

- Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae*. Hunter, S. W. and Brennan, P. J. (A) 623

Diaminodiphenylsulfone,

- Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. (A) 274

Dimorphous leprosy, see Borderline leprosy**DL-Aspartic acid,**

- Enhanced growth of *Mycobacterium lepraemurium* in cell-free liquid medium with DL-aspartic acid. Nakamura, M. (A) 290

DNCB,

- Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., *et al.* (A) 439

Drug(s),

- Deoxyfructo-serotonin: a new drug with anti-leprosy activity. Mester de Parajd, L., *et al.* (A) 274
- In vitro* activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* (A) 157
- In vitro* sensitivity of *Mycobacterium lepraemurium* for antimycobacterial drugs. Portaels, F., *et al.* (A) 142
- Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. (A) 436
- Mutagenic activity of antileprosy drugs and their derivatives. PETERS, J. H., *et al.* (O) 45
- Preliminary study on R761 treatment for leprosy. Li Wenzhong, *et al.* (A) 130
- Rapid, radiolabeled-microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibility. Mittal, A., *et al.* (A) 446
- Recent studies of antileprosy drugs. Shepard, C. C., *et al.* (A) 612
- Selecting drug combinations for treatment of drug-resistant mycobacterial diseases. Nash, D. R. and Steingrube, V. A. (A) 155
- Solid, fragmented and granular index as one of the parameters in drug trials. Sharma, V. D., *et al.* (A) 132

Electron microscopy,

- Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. HIRATA, T. (O) 84
- Electron microscopic study of leprosy in a mangabey monkey (naturally acquired infection). Fukunishi, Y., *et al.* (A) 666
- Electron microscopic study of *Mycobacterium leprae* membrane. SILVA, M. T. and MACEDO, P. M. (O) 219
- The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. (O) 225

ELISA test(s) (enzyme-linked immunosorbent assay),

- Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. (A) 660
- Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* (A) 300
- Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A) 157

Enteropathy,

- Exudative enteropathy due to clofazimine: about a case. Belaube, P., *et al.* (A) 129

Enzyme(s),

- Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. (A) 660

Development of an enzyme-linked immunosorbent assay using arabinomannan from <i>Mycobacterium smegmatis</i> : A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., <i>et al.</i> (A)	443
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A)	157
Eosinophilia,	
Eosinophilia as a result of rifampicin therapy. Nigam, P., <i>et al.</i> (A)	131
Epidemiology,	
<i>Basic Epidemiological Indicators for Monitoring Leprosy Control.</i> Lechat, M. F. and Vanderveken, M. (B)	434
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. (A)	297
Clinical epidemiology of nonlepromatous leprosy among service personnel. (Armed Forces—India). Guha, P. K. (A)	149
Epidemiologic patterns of leprosy in Vallegrande, Bolivia. De Muynck, A. (A)	295
Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. (O)	556
Epidemiology of hanseniasis in the state of Rio Grande do Sul. (Brazil). Bernardi, C. and Ferreira, J. (A)	146
Epidemiology of leprosy in rural population of Pondicherry. (India). Lal, S., <i>et al.</i> (A)	296
Leprosy in wild armadillos (<i>Dasypus novemcinctus</i>) of the Texas Gulf Coast: Epidemiology and mycobacteriology. (U.S.A.). Smith, J. H., <i>et al.</i> (A)	629
Leprosy: the epidemiology of a slow bacterium. Fine, P. E. M. (A)	147
The epidemiology of leprosy in Chaco. (Brazil). Risso, H. I. (A)	296
Workshop on Epidemiology and Statistics in Leprosy held in Guangdong (China). Ye Gan-yun. (N)	430
Epstein-Barr,	
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., <i>et al.</i> (A)	138
Erythema nodosum leprosum (ENL),	
A study of serum fibrinolytic activity in erythema nodosum leprosum (ENL). Jain, V. K., <i>et al.</i> (A)	440
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., <i>et al.</i> (A)	138
An unusual case of erythema nodosum leprosum. Petri, V. (A)	132
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., <i>et al.</i> (O)	321
Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., <i>et al.</i> (A)	134
The immunopathology of erythema nodosum leprosum: The role of extravascular complexes. Ridley, M. J. and Ridley, D. S. (A)	620
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., <i>et al.</i> (A)	647
Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with thalidomide. Saint-André, P., <i>et al.</i> (A)	611
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., <i>et al.</i> (A)	442
Esterase,	
Demonstration of T lymphocytes in leprous granuloma using the acid alpha naphthyl acetate esterase activity. An attempt of quantitative analysis. Gaulier, A., <i>et al.</i> (A)	617
Estrogen,	
Estrogen excretion in pregnant women with leprosy; evidence of diminished fetoplacental function. Duncan, M. E. and Oakey, R. E. (A)	130
Reduced estrogen excretion due to clofazimine? DUNCAN, M. E. and OAKEY, R. E. . . . (C)	112
Ethambutol,	
<i>In vitro</i> activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against <i>Mycobacterium avium-intracellulare</i> complex. Zimmer, B. L., <i>et al.</i> (A)	157

Ethionamide,

- Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., *et al.* (C) 592
- Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., *et al.* (O) 461

Ethiopia,

- Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* (O) 191
- Leprosy in 18-month-old children, Bichena District, Gojjam Administrative Region, Ethiopia. Fekete, E. and Tedla, T. (A) 295
- Skin diseases in Addis Ababa: A preliminary review. Manzur, J. (A) 279
- The age at onset of overt leprosy patients presenting at the Addis Ababa Leprosy Hospital. Alemaychu, A. and Naafs, B. (A) 295

Experimental leprosy,

- Immunological effects of experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* (A) 665
- Quantitative analysis of the sequence of nerve damage in experimental leprosy. Bhat, K. R. and Vaidya, M. C. (A) 292
- Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. (A) 449

Eye(s),

- Blindness from cataract formation in leprosy. Brandt, F., *et al.* (A) 440
- Ocular complications in leprosy. Das, R., *et al.* (A) 276
- The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. (A) 613

Eyebrow(s),

- The distribution of *Mycobacterium leprae* in the hair follicle of the eyebrow. GUMMER, C. L., *et al.* (O) 205

Face,

- Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., *et al.* (A) 280

Factor B,

- Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* (A) 288

Family(ies),

- Familial clustering of leprosy patients in an Israeli village. Barreyo, D. A., *et al.* (A) 146

Feline leprosy,

- Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schieffer, H. B. and Middleton, D. M. (A) 626

Fernandez reaction,

- Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* (O) 481

Fetus,

- Estrogen excretion in pregnant women with leprosy; evidence of diminished fetoplacental function. Duncan, M. E. and Oakey, R. E. (A) 130

Fieldsteel, A. Howard,

- Obituary. Dawson, P. J. and Krahenbuhl, J. L. (Ob) 105

Filariasis,

- Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* (A) 156

Foot,

- “Dorsal incision”—the treatment of complicated forefoot plantar ulcers in the malignant degeneration in chronic ulceration of the leg and foot in leprosy patients; two case reports. Andersen, J. G. (A) 130
- Teaching foot care. Fritschi, E. P. (A) 298
- Ulceration in the neurotrophic foot of Hansen’s disease. Jones, R. O. (A) 453
- Transposition of post-tibial muscles and fasciae for correcting leprosy patient’s drop foot. Lin De-Pao, *et al.* (A) 298

Foot pad(s),

- DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., *et al.* (O) 366
- Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. (A) 436

Freezing,

- Effect of freezing *Mycobacterium leprae* in tissues. Dhople, A. M. (A) 140

Gamma-Interferon,

- Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* (A) 650

Gastric,

- Radiotelemetric examination of gastric function in patients with leprosy. Kenzhebaev, A. Y., *et al.* (A) 278

Genetic(s),

- An approach to study *in vitro* the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., *et al.* (A) 444
- HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* (A) 150

Genome,

- Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. Jacobs, W. R., *et al.* (A) 667
- Deoxyribonucleic acid of *Mycobacterium lepraemurium*: Its genome size, base ratio, and homology with those of other bacteria. Imaeda, T., *et al.* (A) 290

German Leprosy Relief Association,

- German Leprosy Relief Association funds leprosy work. (Thailand). (N) 605
- German Leprosy Relief Association Rehabilitation Fund (GLRARF) services. (India). Gershon, W. and Srinivasan, G. R. (N) 121
- “Pro Merito Melitensi” awards go to three members of the Deutsches Aussatzigen-Hilfswerk. (N) 597
- Southern Sudan to receive DM1.8 million for leprosy work from the German Leprosy Relief Association (GLRA). (N) 595

Germany, Federal Republic of,

- Death of Dr. Lutz Hartdegen. (N) 263
- Hubert Count of Ballestrem awarded Federal Distinguished Service Cross. (N) 596

Glucose,

- Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. (A) 624
- Erythrocyte glucose-6-phosphate dehydrogenase isoenzyme phenotypes in leprosy. SAOJI, A. M. and KELKAR, S. S. (O) 41
- Glucose-6-phosphate dehydrogenase in Hansen’s disease patients receiving sulfones or sulfamethoxypyridazine. Takizawa, H., *et al.* (A) 281

Glycerol,

- Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. (A) 624

- Metabolism of glycerolipids in *Mycobacterium lepraemurium*; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. (A) 653
- Granuloma,**
- Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* (A) 293
- Demonstration of T lymphocytes in leprosy granuloma using the acid alpha naphthyl acetate esterase activity. An attempt at quantitative analysis. Gaulier, A., *et al.* (A) 617
- Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* (A) 620
- Identification of T-cell subpopulations in granuloma annulare. Buechner, S. A., *et al.* . . (A) 298
- In situ* demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* (A) 285
- Infectious granulomas: Exposit from the leprosy model. Skinsnes, O. K. (A) 139
- Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. (A) 621
- Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. (A) 622
- Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. (A) 276
- Role of the major histocompatibility complex in resistance and granuloma formation in response to *Mycobacterium lepraemurium* infection. Adu, H. O., *et al.* (A) 441
- The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* (A) 621
- Griseofulvin,**
- Leprosy downgrading reaction associated with griseofulvin. Shulman, D. G., *et al.* (A) 132
- Guadeloupe,**
- Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* (A) 610
- Guinto, Ricardo S.,**
- Obituary. Binford, C. H. and Reich, C. V. (Ob) 587
- Guyana,**
- An urban community's thoughts about leprosy: a survey of Guyana. Cook, A. (A) 152
- Hand(s),**
- A comparative study of EFMT and sublimis transfer operations in the claw hand. SUNDARARAJ, G. D., *et al.* (O) 197
- A study of palmar dermatoglyphics in leprosy. Nagar, K. S., *et al.* (A) 279
- Evaluation of "power grip and pinch test" in relation to claw hand disability. Kumar, R. P. (A) 153
- Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* (A) 630
- Hansen's disease,**
- 1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. (Argentina). Charosky, C. B. (A) 151
- A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian Hanseniasis. Almeida Neto, E. (A) 273
- Again on "indeterminate leprosy" (alias immature Hanseniasis). RABELLO, F. E., *et al.* (C) 418
- An inquiry into the adoption of the term *Mycobacterium Hansenii*. Rotberg, A. (A) 142
- CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* (A) 618
- Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., *et al.* (A) 278
- Creatinphosphokinase (CPK) activity in the sera of Hanseniasis patients. Garcia, R. R., *et al.* (A) 277

Epidemiology of Hansen's disease in the state of Rio Grande do Sul. (Brazil). Bernardi, C. and Ferreira, J. (A)	146
Glucose-6-phosphate dehydrogenase in Hansen's disease patients receiving sulfones or sulfamethoxypyridazine. Takizawa, H., <i>et al.</i> (A)	281
Hansen's disease in the United States. Hudson, T. and Genessi, J. (A)	295
II International Congress of the College of Hansenology of the Endemic Countries. (N)	263
International seminar schedule for 1984 at the National Hansen's Disease Center. (U.S.A.). (N)	266
IV Brazilian Congress of Hansenology. Bechelli, L. M. (N)	118
Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. (A)	276
Meningoencephalitis due to <i>Cryptococcus neoformans</i> complicated by arteriosclerotic vascular insufficiency in virchowian Hansen's disease. Fleury, R. N., <i>et al.</i> (A)	277
Neuropathies in Hansen's disease. CHAROSKY, C. B., <i>et al.</i> (E)	576
Otolaryngologic manifestations of Hansen's disease. Stevens, M. H. and Nielsen, D. R. (A)	615
Phagocytosis and lysis of <i>Candida albicans</i> and <i>Candida pseudotropicalis</i> by polymorphonuclear leukocytes of Hansen's disease patients. Fliess, E. L., <i>et al.</i> (A)	283
Positioning of borderline and indetermined groups in the Hansen's disease classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. (A)	128
Prevalence of Australia antigen (HBsAg) in Hansen's disease patients. Sarno, E. N., <i>et al.</i> (A)	281
Some aspects of Hansen's disease in the region of Londrina, Parana, 1968-1978. (Brazil). Tornero, N., <i>et al.</i> (A)	297
Some aspects of Hansen's disease in the region of Londrina, Parana, 1968-1978. I. General characteristics. (Brazil). Asseis, E. A., <i>et al.</i> (A)	145
Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., <i>et al.</i> (A)	283
The "Hansen-nergic fringe" and renewed doubts about vaccination. ROTBERG, A. (C)	411
The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. (A)	613
Ulceration in the neurotrophic foot of Hansen's disease. Jones, R. O. (A)	453
Waldemar F. Kirchheimer, M.D., Ph.D., retires from National Hansen's Disease Center (U.S.A.). Hastings, R. C. (N)	124
Heiser Program, The,	
The Heiser Program for Research in Leprosy; 1984 opportunities. (N)	431
Hepatitis,	
Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., <i>et al.</i> (A)	156
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., <i>et al.</i> (O)	461
Hepatitis-B-surface antigen (HBsAg) in leprosy patients. Balakrishnan, S., <i>et al.</i> (A)	439
Histoid leprosy,	
Histoid lepromas. Ramos-Caro, F. A. (A)	280
Preliminary observation on 20 cases of histoid leproma. Zhang Jun-Tan, <i>et al.</i> (A)	133
Histology,	
<i>Mycobacterium leprae</i> infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., <i>et al.</i> (A)	293
Sequential histological study of lepromin reaction. DESIKAN, K. V., <i>et al.</i> (O)	473
Histopathology,	
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, <i>et al.</i> (A)	135
Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., <i>et al.</i> (A)	278
The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of <i>Mycobacterium lepraemurium</i> . Adu, H. O., <i>et al.</i> (A)	449

HLA,

- An approach to study *in vitro* the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., *et al.* (A) 444
- HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. (China). Xu Keyu, *et al.* (A) 150
- HLA and leprosy. II. The associate of HLA-DR2 with lepromatous leprosy. Xu Keyu, *et al.* (A) 629
- HLA and susceptibility to leprosy. Serjeantson, S. W. (A) 451
- HLA antigens in leprosy patients. Bale, U. M., *et al.* (A) 146
- HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* (A) 150
- In vitro* lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. (C) 110
- Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., *et al.* (A) 283
- Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. (A) 137

Hydrocortisone,

- Hydrocortisone production in lepromatous patients with insulin load. BALYBIN, E. S. and NAZAROV, K. I. (O) 18

Hypersensitivity,

- Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* (A) 155
- Induction of delayed type hypersensitivity against ultrasonicated *Mycobacterium lepraemurium* bacilli without simultaneous local reactivity against live bacilli. Lovik, M. and Closs, O. (A) 625

ICRC bacilli,

- Antileprosy potentials of ICRC vaccine. A study in patients and healthy volunteers. DEO, M. G., *et al.* (O) 540
- Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* (O) 466

IgA,

- IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* (A) 136
- Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., *et al.* (O) 22

IgE,

- IgE in leprosy. LYNCH, N. R. and LOPEZ, R. I. (C) 416
- IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* (O) 169
- Reply to Drs. Lynch and Lopez's letter. NUTI, M., *et al.* (C) 417

IgG,

- High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* (A) 138
- IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* (A) 136

IgM,

- IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* (A) 136

ILEP,

- Guidelines for the Campaign Against Leprosy. (B) 433
- ILEP members aid 1.23 million leprosy patients. (N) 597

IMMLEP,

- IMMLEP and THELEP seek trial sites. (N) 604
- Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific

Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14-16 February 1983. (O)	500
Immune complexes,	
Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., <i>et al.</i> (A)	617
Circulating immune complexes in patients with nodular lepromatous leprosy. Vazquez-Escobosa, C., <i>et al.</i> (A)	289
Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., <i>et al.</i> (A)	620
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., <i>et al.</i> (A)	442
Immune responses,	
Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., <i>et al.</i> (A)	301
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., <i>et al.</i> (O)	33
Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., <i>et al.</i> (A)	285
Immune-response gene-associated antigens (Ia/DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. (A)	632
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., <i>et al.</i> (A)	301
Immunodiffusion,	
Immunodiffusion analyses of some diphtheroid organisms isolated from patients with leprosy. RIDELL, M. (O)	179
Immunoglobulin(s),	
Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., <i>et al.</i> (O)	22
Immunoglobulin deposits in leprosy skin. Higashi, G. I., <i>et al.</i> (A)	440
Immunoglobulins in the urine of leprosy patients. SENGUPTA, U., <i>et al.</i> (C)	409
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., <i>et al.</i> (A)	132
Salivary immunoglobulin and antibody activities in leprosy. Abe, M., <i>et al.</i> (A)	657
Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Hari-krishnan, S., <i>et al.</i> (A)	134
Immunology,	
A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., <i>et al.</i> (O)	7
A single subcutaneous inoculation of 10 ⁷ armadillo-derived irradiated <i>Mycobacterium leprae</i> evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., <i>et al.</i> (A)	450
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., <i>et al.</i> (A)	300
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. (A)	300
Immune-response gene-associated antigens (Ia-DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. (A)	632
Immunologic profile in patients with nodular lepromatous leprosy. Ramos-Zepeda, R., <i>et al.</i> (A)	137
Immunological aspects of leprosy. Harboe, M. and Closs, O. (A)	618
Immunological effects of experimental leprosy in the mangabey (<i>Cercocebus atys</i>). Martin, L. N., <i>et al.</i> (A)	665
Immunological profile in lepromatous leprosy patients; our experience. Gimenez, M. M., <i>et al.</i> (A)	284

Immunological research in tuberculosis: Memorandum from a WHO meeting. (A)	299
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., <i>et al.</i> (A)	132
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., <i>et al.</i> (A)	650
Study of immunological parameters in patients with different clinical forms of leprosy; the influence of treatment. Bottasso, O. A., <i>et al.</i> (A)	133
Immunopharmacology,	
The immunopharmacology of antileprosy agents. Anderson, R. (A)	609
Immunosuppression,	
Mechanism of immunosuppression in leprosy: Presence of suppressor factor(s) from macrophages of lepromatous patients. Salgame, P. R., <i>et al.</i> (A)	620
Probable mechanisms of immunosuppression in leprosy. Bottasso, O. A., <i>et al.</i> (A)	282
Indeterminate leprosy,	
Again on "indeterminate leprosy" (alias immature hanseniasis). RABELLO, F. E., <i>et al.</i> (C)	418
Indeterminate leprosy. KLOKKE, A. H. (C)	256
Reply to Dr. Klokke's letter. BROWNE, S. G. (C)	256
Reply to Dr. Rabello, <i>et al.</i> 's letter. JOPLING, W. H. (C)	420
Reply to Dr. Rabello, <i>et al.</i> 's letter. PETTIT, J. H. S. (C)	420
India,	
A review of five years leprosy work in an urban area Rayadurg. Krishnamoorthy, K. V., <i>et al.</i> (A)	296
A 20-year study of the leprosy control programme at the Government Leprosy Treatment and Study Centre at Tirukoilur in South India. Radhakrishna, S., <i>et al.</i> (A)	149
Absenteeism during treatment of leprosy: An analysis of its causes as evidenced by a survey in South India. Vellut, C., <i>et al.</i> (A)	438
Action plans for leprosy control meeting. Sansarricq, H. (N)	263
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. (A)	297
Clinical epidemiology of nonlepromatous leprosy among service personnel. Guha, P. K. (A)	149
Comparison of slum survey, school survey and health education as methods of detection of leprosy cases in an urban area. Soni, S. and Ingle, P. (A)	297
DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., <i>et al.</i> (O)	366
Dr. Nilakanta Rao awarded Damien-de-Veuster Medal. Christian, M. (N)	264
Endemicity of leprosy in the Union Territory of Chandigarh and surrounding states. Kaur, S., <i>et al.</i> (A)	149
Epidemiology of leprosy in rural population of Pondicherry. Lal, S., <i>et al.</i> (A)	296
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., <i>et al.</i> (O)	382
Gandhi Memorial Leprosy Foundation Report 1981–82. (N)	267
Geo-ecology of leprosy with special reference to West Bengal. Banerjee, B. and Hazra, J. (A)	627
German Leprosy Relief Association Rehabilitation Fund (GLRARF) services. Gershon, W. and Srinivasan, G. R. (N)	121
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., <i>et al.</i> (A)	138
Indian railways launch antileprosy campaign in collaboration with Bombay Leprosy Project. Revankar, C. R. (N)	430
JALMA 1981 annual report. (N)	264
"Jal Neti" a yoga technique for nasal comfort and hygiene in leprosy patients. Appa Rao, A. V. N., <i>et al.</i> (A)	275

Leprosy workshop held in Bombay. Naik, S. S. (N)	431
Multidrug regimen project initiated. Christian, M. (N)	265
Nalgonda Leprosy Center treating 7600 leprosy patients. (N)	597
Observance of Antileprosy Week by Bombay Leprosy Project. Revankar, C. R. (N)	431
Padma Shri awarded to Dr. Ganapati. Christian, M. (N)	265
Proceedings of 1983 Eastern Regional Leprosy Workers' Conference. Chaudhury, D. S. (N)	267
Prospects for a <i>Mycobacterium leprae</i> vaccine against leprosy after Madras. Stoner, G. L. (A)	645
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. (O)	500
Response to dapsone (DDS) monotherapy in leprosy patients of Gudiyatham Taluk, South India: Comparison between the 1960s and the 1970s. ALMEIDA, J. G., <i>et al.</i> (O)	378
Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., <i>et al.</i> (O)	385
Tuberculosis in India—the prospect. Sivaraman, S. (A)	635
XII International Leprosy Congress. (N)	114
..... (N)	424
..... (N)	598
XII International Leprosy Congress abstract deadline extended. (N)	265
XIII Biennial Conference of Indian Association of Leprologists. (N)	269
INFOLEP,	
INFOLEP 1982 Annual Report. (N)	603
Injection(s),	
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., <i>et al.</i> (O)	191
Sensitization or tolerance to <i>Mycobacterium leprae</i> antigen by route of injection. Shep- ard, C. C., <i>et al.</i> (A)	138
Sex differences in the absorption of dapsone after intramuscular injection. MODDERMAN, E. S. M., <i>et al.</i> (O)	359
Inoculation,	
A single subcutaneous inoculation of 10 ⁷ armadillo-derived irradiated <i>Mycobacterium</i> <i>leprae</i> evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., <i>et al.</i> (A)	450
<i>Mycobacterium leprae</i> infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., <i>et al.</i> (A)	293
Insulin,	
Hydrocortisone production in lepromatous patients with insulin load. BALYBIN, E. S. and NAZAROV, K. I. (O)	18
Interleukin,	
Deficit of interleukin 2 production associated with impaired T-cell proliferative re- sponses in <i>Mycobacterium lepraemurium</i> infection. Hoffenbach, A., <i>et al.</i> (A)	292
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., <i>et al.</i> (A)	649
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuber- culoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., <i>et al.</i> (A)	650
International Congress for Tropical Medicine and Malaria (ICTMM),	
Meeting announcement. (N)	263
INTERNATIONAL JOURNAL OF LEPROSY (IJL),	
On the Journal's 50th anniversary. TRAN HUU-NGOAN. (C)	262
Reviewers. (—)	673
Statement of financial condition. (—)	455

Statement of ownership, management and circulation.	(—)	460
The 1982 Journal—a continuing perspective. HASTINGS, R. C.	(E)	89
International Leprosy Association (ILA),		
Organization and membership.	(—)	674
International Leprosy Congress, XII,		
Abstract deadline extended.	(N)	265
Announcement and preliminary program.	(N)	114
Program.	(N)	424
.	(N)	598
Iridocyclitis,		
Clinical observation on iridocyclitis in leprosy patients. Acharya, B. P.	(A)	612
Isoniazid (INH),		
<i>In vitro</i> activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against <i>Mycobacterium avium-intracellulare</i> complex. Zimmer, B. L., <i>et al.</i>	(A)	157
Isoprinosine,		
Utilization of an immunomodulant (isoprinosine) in multibacillary leprosy. Preliminary study. Saint-André, P., <i>et al.</i>	(A)	611
Israel,		
Familial clustering of leprosy patients in an Israeli village. Barreyo, D. A., <i>et al.</i>	(A)	146
Italy,		
Leprosy in Italy. GRECO, D. and GALANTI, M. R.	(O)	495
Raoul Follereau grant for leprosy research.	(N)	429
Japan,		
Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., <i>et al.</i>	(A)	617
Immunogenetical studies of leprosy in Japan. Ozawa, T., <i>et al.</i>	(A)	655
Sasakawa Memorial Health Foundation publications available in English.	(N)	603
Kellersberger Memorial Lecture,		
The Kellersberger Memorial Lecture 1981: The general situation of leprosy in the world. Sansarricq, H.	(A)	272
Kinetics,		
Modification of the kinetics of growth of <i>Mycobacterium leprae</i> by a group of corynebacteria. Delville, J., <i>et al.</i>	(A)	290
Lamprene*,		
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene*) in the treatment of prurigo nodularis. BELAUBE, P., <i>et al.</i>	(O)	328
Latin America,		
Policy and strategy for leprosy control programs. Romero, A.	(A)	628
Lecithin,		
Stimulating effects of lecithin and cholesterol on the growth of <i>Mycobacterium leprae-murium</i> in cell-free liquid medium. Nakamura, M.	(A)	141
Leg(s),		
Malignant degeneration in chronic ulceration of the leg and foot in leprosy patients; two case reports. Andersen, J. G.	(A)	130
Leishmaniasis,		
Diffuse anergic leishmaniasis (lepromatous leishmaniasis). Gatti, C. F. and Sampaio, A. P.	(A)	632
Leonard Wood Memorial,		
Leonard Wood Memorial research grant for early diagnosis of leprosy.	(A)	605
Leproma,		
An unusual location of leproma of bone; a case report. ANDERSEN, J. G. and WARN-DORFF, J.	(O)	203

Diffuse lepromatosis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. (A)	281
Histoid lepromas. Ramos-Caro, F. A. (A)	280
Preliminary observation on 20 cases of histoid leproma. Zhang Jun-Tan, <i>et al.</i> (A)	133
Lepromatous leprosy,	
A case report of lepromatous leprosy. Mishner, H. S. and McTighe, A. H. (A)	279
A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., <i>et al.</i> (O)	7
A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. (A)	273
A comparison of the incidence of type 2 reactions in lepromatous leprosy with two regimens of treatment. Manungo, J. and Thomas, J. E. P. (A)	130
A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., <i>et al.</i> (A)	280
A study of type 2 reactions in lepromatous leprosy. Manungo, J. and Thomas, J. E. P. (A)	131
An unusual presentation of lepromatous leprosy. Selliah, K. and Ayasamy, A. (A)	614
Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, <i>et al.</i> (A)	135
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. (A)	131
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., <i>et al.</i> (A)	288
Chemotherapy of non-lepromatous leprosy. (A)	609
Circulating immune complexes in patients with nodular lepromatous leprosy. Vazquez-Escobosa, C., <i>et al.</i> (A)	289
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., <i>et al.</i> (O)	321
Defect in the generation of cytotoxic T cells in lepromatous leprosy. Stach, J.-L., <i>et al.</i> (A)	444
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., <i>et al.</i> (O)	382
Gonadotropin, prolactin, and thyrotropin secretion in lepromatous leprosy. Shilo, S., <i>et al.</i> (A)	132
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., <i>et al.</i> (A)	138
HLA and leprosy. II. The associate of HLA-DR2 with lepromatous leprosy. Xu Keyu, <i>et al.</i> (A)	629
Hydrocortisone production in lepromatous patients with insulin load. BALLYBIN, E. S. and NAZAROV, K. I. (O)	18
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., <i>et al.</i> (A)	442
Immunohistological studies of skin biopsies from patients with lepromatous leprosy. Mshana, R. N., <i>et al.</i> (A)	286
Immunologic profile in patients with nodular lepromatous leprosy. Ramos-Zepeda, R., <i>et al.</i> (A)	137
Immunological profile in lepromatous leprosy patients; our experience. Gimenez, M. M., <i>et al.</i> (A)	284
Impairment in the number of circulating T lymphocytes in lepromatous leprosy. Preliminary study. Kodjovi, M., <i>et al.</i> (A)	135
Involvement of subcutaneous veins in lepromatous leprosy. MUKHERJEE, A., <i>et al.</i> (O)	1
Lepromatous leprosy in children. (An account of the last three observations.) Ravettini, B. A., <i>et al.</i> (A)	614
Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. (A)	628

- Leprosy XII. T-cell subsets in lepromatous leprosy. Lim, S. D., *et al.* (A) 443
- Leprosy, borderline-lepromatous, and cytomegalovirus infection. Kruyt, J. A., *et al.* ... (A) 278
- Meningoencephalitis due to *Cryptococcus neoformans* complicated by arteriosclerotic vascular insufficiency in virchowian hanseniasis. Fleury, R. N., *et al.* (A) 277
- Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., *et al.* (A) 442
- Monocyte suppressor factor(s) and release of *in vitro* suppression in lepromatous leprosy. Nath, I., *et al.* (A) 669
- Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* (A) 287
- Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. (A) 438
- Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., *et al.* (A) 441
- Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* (A) 443
- Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* (A) 610
- Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* (O) 385
- Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* (O) 466
- Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., *et al.* (A) 129
- SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* (A) 134
- Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Hari-krishnan, S., *et al.* (A) 134
- Serum lipoproteins in lepromatous leprosy. Kher, J. R., *et al.* (A) 441
- Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoïd leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* (A) 650
- Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., *et al.* (A) 134
- T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Hargewoin, A., *et al.* (A) 618
- Ultrastructural alterations of *Mycobacterium leprae* in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., *et al.* (A) 291
- Lepromin,**
- Corticosteroids and lepromin sensitivity. Kundu, S. K., *et al.* (A) 131
- Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved *Mycobacterium w.* CHAUDHURI, S., *et al.* (O) 159
- Sequential histological study of lepromin reaction. DESIKAN, K. V., *et al.* (O) 473
- Variable lepromin response to *Mycobacterium leprae* in resistant armadillos. JOB, C. K., *et al.* (O) 347
- Leprosy,**
- Actualizaciones Leprológica.* Gatti, J. C., *et al.* (B) 606
- An Atlas of Leprosy.* Guinto, R. S., *et al.* (B) 606
- Articular manifestations in leprosy. Bonvoisin, B., *et al.* (A) 613
- Attitude of doctors to working in leprosy. Ramanthan, U. and Ramu, G. (A) 271
- Biblical leprosy as compared to present-day leprosy. Baillie, R. A. and Baillie, E. E. ... (A) 271
- Grid system and body diagram for leprosy. Boerrigter, G. (A) 613
- Integration of leprosy into general health services in an urban area—a feasibility study. Revankar, C. R., *et al.* (A) 128
- Leprosy. Hendrick, S. S. and Wilkin, J. K. (A) 436
- Leprosy. Stingl, P. (A) 436
- Leprosy as a correlate of anxiety on the self-erosion dimension. Chauhan, N. S., *et al.* (A) 152

Leprosy today. Shepard, C. C. (A)	272
Leprosy, an overview. Goihman-Yahr, M. (A)	437
Leprosy; the epidemiology of a slow bacterium. Fine, P. E. M. (A)	147
Pattern of leprosy in a city hospital. SEHGAL, V. N., <i>et al.</i> (O)	354
Risks of treating leprosy in a general hospital. NELSON, K. E. and SCHAUF, V. (C)	413
The complexities of health education in leprosy. Dharmalingam, R. and Shanmugan, P. (A)	627
The method of retrieval of data for statistical registration of leprosy patients. Agüero, H., <i>et al.</i> (A)	451
Tzaraat—"biblical leprosy." Freilich, A. R. (A)	609
Lesions,	
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, <i>et al.</i> (A)	135
Atrophic lesions of the tongue in leprosy patients. Prabhu, S. R. and Daftary, D. K. (A)	280
Biological properties of diphtheroid bacteria (LDC) isolated from human leprosy lesions. Delville, J., <i>et al.</i> (A)	140
Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., <i>et al.</i> (A)	280
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., <i>et al.</i> (A)	613
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., <i>et al.</i> (A)	650
T cell subsets in leprosy lesions: <i>in situ</i> characterization using monoclonal antibodies. Narayanan, R. B., <i>et al.</i> (A)	287
T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., <i>et al.</i> (A)	274
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. (A)	137
Leukocytes,	
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)	294
Phagocytosis and lysis of <i>Candida albicans</i> and <i>Candida pseudotropicalis</i> by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., <i>et al.</i> (A)	283
Phagocytosis of <i>Candida albicans</i> by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., <i>et al.</i> (A)	287
Levamisole,	
Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., <i>et al.</i> (A)	439
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. (A)	438
Lipid(s),	
Fatty acid and polar lipid analysis as tools in the identification of <i>Mycobacterium leprae</i> and some related slow-growing mycobacterial species. Anderson, O., <i>et al.</i> (A)	445
Mycobacterial lipids in infected tissue samples. Young, D. B. (A)	292
The phthiocerol-containing surface lipids of <i>Mycobacterium leprae</i> —a perspective of past and present work. BRENNAN, P. J. (E)	387
Lipoprotein,	
Delayed hypersensitivity eliciting lipoprotein antigen of <i>Mycobacterium tuberculosis</i> H37Rv. Deshpande, J. M., <i>et al.</i> (A)	155
Serum lipoproteins in lepromatous leprosy. Kher, J. R., <i>et al.</i> (A)	441
Liposome,	
Growth stimulation of <i>Mycobacterium lepraemurium</i> by liposome in cell-free liquid medium. Nakamura, M. (A)	141
Liver(s),	
Bacteriological studies of armadillo livers infected with <i>Mycobacterium leprae</i> . Portaels, F., <i>et al.</i> (A)	141

Lucio leprosy,

- Diffuse lepromatosis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. (A) 281
- Lucio leprosy. Gilbert, E., *et al.* (A) 284

Lymphocyte(s),

- Active and total E-rosette forming T-lymphocytes in pulmonary tuberculosis. Prabhu, R. and Reddy, M. V. (A) 634
- Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* (A) 156
- Binding of phosphatidylethanolamine and phosphatidylinositol to OKT8+ lymphocytes activates suppressor cell activity. Wadee, A. A. and Rabson, A. R. (A) 445
- Demonstration of T lymphocytes in leprous granuloma using the acid alpha naphthyl acetate esterase activity. An attempt at quantitative analysis. Gaulier, A., *et al.* (A) 617
- Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* (A) 132
- Impairment in the number of circulating T lymphocytes in lepromatous leprosy. Preliminary study. Kodjovi, M., *et al.* (A) 135
- In situ* characterization of T lymphocyte subsets in the reactional states of leprosy. Modlin, R. L., *et al.* (A) 619
- In situ* demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* (A) 285
- In vitro* lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. (C) 110
- Lymphocyte subpopulations in mice infected with *Mycobacterium leprae*. Ganguly, N. K., *et al.* (A) 450
- Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* (A) 443
- Subpopulations of T and B lymphocytes in leprosy patients. Finiasz, M. R., *et al.* (A) 283
- T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., *et al.* (A) 274
- The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* (A) 133
- Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., *et al.* (A) 286
- Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* (A) 647

Lysis,

- Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* (A) 283
- The microcolonial texture and demonstration of a phage-like lysis in the "Douglas" strain of *Mycobacterium lepraemurium*. Sula, L. (A) 448

Macrophage(s),

- Adherence of *Mycobacterium leprae* to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. (A) 284
- Alterations in the membrane of macrophages from leprosy patients. Birdi, T. J., *et al.* (A) 616
- Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae*. Kurup, I. G. and Mahadevan, P. R. (A) 135
- Foam—the result of an interaction between unactivated macrophages and dead *Mycobacterium leprae*? JOB, C. K., *et al.* (C) 256
- Increased H₂O₂ production by splenic murine macrophages associated with susceptibility of *Mycobacterium lepraemurium* infection. Sankaran, K., *et al.* (A) 652
- Lack of correlation between morphological index and viability as assessed by the uptake of ³H-thymidine by macrophage resident *M. leprae*. Sathish, M., *et al.* (A) 142
- Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and functional changes of peritoneal and splenic macrophages *in vitro*. Ha, D. K. K., *et al.* (A) 292

Mechanism of immunosuppression in leprosy: Presence of suppressor factor(s) from macrophages of lepromatous patients. Salgame, P. R., <i>et al.</i> (A)	620
Radiolabelled <i>M. leprae</i> resident in human macrophage cultures as an <i>in vitro</i> indicator of effective immunity in human leprosy. Prasad, H. K., <i>et al.</i> (A)	137
Rapid, radiolabeled-microculture method that uses macrophages for <i>in vitro</i> evaluation of <i>Mycobacterium leprae</i> viability and drug susceptibility. Mittal, A., <i>et al.</i> (A)	446
Serum macrophage migration inhibition activity in patients with leprosy. Rea, T. H. and Yoshida, T. (A)	288
Macular leprosy,	
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., <i>et al.</i> (A)	132
Madrid classification,	
Analysis of the inter- and intrapathological concordances and discordances in a comparative study of Madrid and Ridley-Jopling classifications of leprosy. Haddad, N., <i>et al.</i> (A)	435
Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., <i>et al.</i> (A)	435
Malaysia,	
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7-11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. (B)	608
Mali,	
Further results on dapsone-resistant leprosy in Bamako (Mali). Baquillon, G., <i>et al.</i> (A)	273
Mallorca,	
Assistance to patients on Mallorca in ancient times. Mas, A. C. and Vaquer, R. R. (A)	271
Martinique,	
Resistance of <i>Mycobacterium leprae</i> to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., <i>et al.</i> (A)	610
Metabolism,	
Cholesterol metabolism of macrophages in relation to the presence of <i>Mycobacterium leprae</i> . Kurup, I. G. and Mahadevan, P. R. (A)	135
Infection by <i>Mycobacterium haemophilum</i> , a metabolically fastidious acid-fast bacillus. Mouldsdale, M. T., <i>et al.</i> (A)	301
Metabolism of carbon sources of <i>Mycobacterium leprae</i> : a preliminary report. Wheeler, P. R. (A)	143
Metabolism of glycerolipids in <i>Mycobacterium lepraemurium</i> ; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. (A)	653
Mexico,	
V International Congress of Tropical Dermatology to meet in Mexico City. (N)	266
Mice,	
A single subcutaneous inoculation of 10 ⁷ armadillo-derived irradiated <i>Mycobacterium leprae</i> evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., <i>et al.</i> (A)	450
Comparative immunogenicity of BCG and <i>Mycobacterium leprae</i> in normal and in <i>M. leprae</i> -tolerant mice. Shepard, C. C. (A)	646
Comparison of the immunogenicity of vaccines prepared from viable <i>Mycobacterium bovis</i> BCG, heat-killed <i>Mycobacterium leprae</i> , and a mixture of the two for normal and <i>M. leprae</i> -tolerant mice. Shepard, C. C., <i>et al.</i> (A)	626
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)	294

- Evidence for generation of suppressor T cells in *Mycobacterium lepraemurium*-infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hirooka, Y. (A) 450
- Inbred mouse strain resistance to *Mycobacterium lepraemurium* follows the *Ity/Lsh* pattern. Brown, I. N., *et al.* (A) 143
- Lymphocyte subpopulations in mice infected with *Mycobacterium leprae*. Ganguly, N. K., *et al.* (A) 450
- Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. (A) 294
- Peripheral neuropathy in mice infected with *Mycobacterium lepraemurium*. Lefford, M. J., *et al.* (A) 651
- Suppressor cells of mouse and man. What is the evidence that they contribute to the aetiology of the mycobacterioses? Rook, G. A. W. (A) 137
- Survival of *Mycobacterium leprae* in mice administered several antibiotics *per os*. LEVY, L., *et al.* (C) 254
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. II. On the cases with subcutaneous infection. Tanemura, M. (A) 145
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. III. On the cases intraperitoneally infected with small dose. Tanemura, M., *et al.* (A) 145
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. IV. Comparative observations on virulence of four strains of *M. avium*. Kawaguchi, Y., *et al.* ... (A) 144
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* (A) 144
- Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* (A) 625
- The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium*. Adu, H. O., *et al.* (A) 449
- The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* (A) 625
- Mice, nude,**
- Mycobacterium leprae* infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* (A) 293
- Nude mice as a model for chemotherapy of leprosy. Kohsaka, K., *et al.* (A) 437
- Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* ... (A) 649
- Microscopy,**
- Technical Guide for Smear Examination for Leprosy by Direct Microscopy*. Leiker, D. L. and McDougall, A. C. (B) 606
- Mitsuda reaction,**
- Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* (O) 481
- Monkeys,**
- Experimental transmission of leprosy in African green monkeys (*Cercopithecus aethiops*) and the rhesus monkey (*Macaca mulatta*). Wolf, R. H., *et al.* (A) 664
- Monocytes,**
- Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* (A) 285
- Morphology,**
- Isolation and study of the morphological properties and immunogenicity of *Mycobacterium tuberculosis*. Khomenko, A. G., *et al.* (A) 633
- Lack of correlation between morphological index and viability as assessed by the uptake of ³H-thymidine by macrophage resident *M. leprae*. Sathish, M., *et al.* (A) 142
- Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and

functional changes of peritoneal and splenic macrophages <i>in vitro</i> . Ha, D. K. K., <i>et al.</i>	(A)	292
Morphology of bacteriophages from <i>Mycobacterium lepraemurium</i> . Rastogi, N. and David, H. L.	(A)	142
Mouse foot-pad growth patterns of <i>M. leprae</i> in relation to Morphological Index. Ven- kataramaniah, H. N., <i>et al.</i>	(A)	295
Muscle(s),		
Reproducibility of sensory testing and voluntary muscle testing in evaluating the treat- ment of acute neuritis in leprosy patients. Lewis, S.	(A)	279
Transposition of post-tibial muscles and fasciae for correcting leprosy patient's drop foot. Lin De-Pao, <i>et al.</i>	(A)	298
Mycobacteria,		
Activity of amikacin against mycobacteria <i>in vitro</i> and in murine tuberculosis. Sanders, W. E., Jr., <i>et al.</i>	(A)	156
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., <i>et al.</i>	(A)	623
Dissociation between allergy and immunity in mycobacterial infections. Turk, J. L.	(A)	288
Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., <i>et al.</i>	(A)	620
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schie- fer, H. B. and Middleton, D. M.	(A)	626
Fatty acid and polar lipid analysis as tools in the identification of <i>Mycobacterium leprae</i> and some related slow-growing mycobacterial species. Anderson, O., <i>et al.</i>	(A)	445
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in <i>Mycobacterium leprae</i> and other mycobacteria. Miller, R. A., <i>et al.</i>	(A)	655
Growth of mycobacteria in relation to the pH of the medium. Portaels, F. and Pattyn, S. R.	(A)	446
<i>In vitro</i> induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T.	(A)	443
Mycobacterial lipids in infected tissue samples. Young, D. B.	(A)	292
Selecting drug combinations for treatment of drug-resistant mycobacterial diseases. Nash, D. R. and Steingrube, V. A.	(A)	155
Sensitivity of mycobacteria to dapsone. Portaels, F., <i>et al.</i>	(A)	142
Sensitization and immunization of mycobacteria. FREERKSEN, E.	(C)	261
Serological approaches for the characterization of catalase in tissue-derived mycobac- teria. Katoch, V. M., <i>et al.</i>	(A)	624
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W.	(A)	283
<i>The Biology of Mycobacteria</i> . Vol. 1. Physiology, Identification and Classification. Rat- ledge, C. and Stanford, J., eds.	(B)	127
The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Nye, P. M., <i>et al.</i>	(A)	287
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S.	(O)	225
Mycobacteriosis,		
A new communication on natural mycobacteriosis in armadillos (<i>Dasypus novemcinctus</i> Linn.). Martinez, A. R., <i>et al.</i>	(A)	144
Ulcerative cutaneous mycobacteriosis. Lavalle, P., <i>et al.</i>	(A)	633
<i>Mycobacterium avium</i>,		
Comparative ultrastructure of <i>Mycobacterium leprae</i> and <i>M. avium</i> grown in experi- mental hosts. Rastogi, N., <i>et al.</i>	(A)	447
<i>In vitro</i> activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against <i>Mycobacterium avium-intracellulare</i> complex. Zimmer, B. L., <i>et al.</i>	(A)	157
Infection with <i>Mycobacterium avium-intracellulare</i> and the protective effects of bacille Calmette-Guérin. Edwards, M. L., <i>et al.</i>	(A)	453

- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. II. On the cases with subcutaneous infection. Tanemura, M. (A) 145
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. III. On the cases intraperitoneally infected with small dose. Tanemura, M., *et al.* (A) 145
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. IV. Comparative observations on virulence of four strains of *M. avium*. Kawaguchi, Y., *et al.* (A) 144
- Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* (A) 144
- Mycobacterium avium-intracellulare*,**
- In vitro* activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* (A) 157
- Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guérin. Edwards, M. L., *et al.* (A) 453
- Mycobacterium bovis*,**
- Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. (A) 299
- Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae*, and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* (A) 626
- Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* (A) 285
- Mycobacterium haemophilum*,**
- Infection by *Mycobacterium haemophilum*, a metabolically fastidious acid-fast bacillus. Mouldsdale, M. T., *et al.* (A) 301
- Mycobacterium hansenii*,**
- An inquiry into the adoption of the term *Mycobacterium hansenii*. Rotberg, A. (A) 142
- Mycobacterium leprae*,**
- A serological test for leprosy with a glycolipid specific for *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. (A) 622
- A single subcutaneous inoculation of 10⁷ armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* (A) 450
- Adherence of *Mycobacterium leprae* to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. (A) 284
- Adsorption of mycobacteriophages on *Mycobacterium leprae*: taxonomic significance. David, H. L., *et al.* (A) 140
- Bacteriological studies of armadillo livers infected with *Mycobacterium leprae*. Portaels, F., *et al.* (A) 141
- Bacteriology of *Mycobacterium leprae*. Pattyn, S. R. (A) 624
- Biochemical investigation of the peribacillary substance of *Mycobacterium leprae*. Fukunishi, Y., *et al.* (A) 668
- Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. (A) 624
- Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae*. Kurup, I. G. and Mahadevan, P. R. (A) 135
- Comparative immunogenicity of BCG and *Mycobacterium leprae* in normal and in *M. leprae*-tolerant mice. Shepard, C. C. (A) 646
- Comparative ultrastructure of *Mycobacterium leprae* and *M. avium* grown in experimental hosts. Rastogi, N., *et al.* (A) 447
- Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae*, and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* (A) 626
- Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. Jacobs, W. R., *et al.* (A) 667
- Crossreactivity between *Mycobacterium leprae* and various actinomycetes and related organisms. RIDELL, M. (O) 185

Definition of species-specific and cross-reactive antigenic determinants of <i>Mycobacterium leprae</i> using monoclonal antibodies. Ivanyi, J., <i>et al.</i> (A)	619
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of <i>Mycobacterium leprae</i> . Young, D. B. and Buchanan, T. M. (A)	660
Effect of freezing <i>Mycobacterium leprae</i> in tissues. Dhople, A. M. (A)	140
Effect of purified protein derivative and sonicates of <i>Mycobacterium leprae</i> and <i>Mycobacterium bovis</i> BCG on thromboplastin response in human monocytes. Lyberg, T., <i>et al.</i> (A)	285
Effect of treatment on antibody activity against <i>Mycobacterium leprae</i> antigen 7 in tuberculoid leprosy. DAHLE, J. S., <i>et al.</i> (O)	312
Effects of vaccination with <i>Mycobacterium leprae</i> on local cell-mediated immunity. Ridell, P.-R., <i>et al.</i> (A)	645
Electron microscopic study of <i>Mycobacterium leprae</i> membrane. SILVA, M. T. and MACEDO, P. M. (O)	219
Evaluation of the significance of antibodies to phenolic glycolipid of <i>Mycobacterium leprae</i> in leprosy patients and their contacts. Buchanan, T. M., <i>et al.</i> (A)	658
Exochelin-mediated iron uptake into <i>Mycobacterium leprae</i> . HALL, R. M., <i>et al.</i> (O)	490
Fatty acid and polar lipid analysis as tools in the identification of <i>Mycobacterium leprae</i> and some related slow-growing mycobacterial species. Anderson, O., <i>et al.</i> (A)	445
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed <i>Mycobacterium leprae</i> : Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., <i>et al.</i> (O)	481
Foam—the result of an interaction between unactivated macrophages and dead <i>Mycobacterium leprae</i> ? JOB, C. K., <i>et al.</i> (C)	256
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from <i>Mycobacterium leprae</i> . Hunter, S. W. and Brennan, P. J. (A)	623
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in <i>Mycobacterium leprae</i> and other mycobacteria. Miller, R. A., <i>et al.</i> (A)	655
Gas chromatography of constitutive fatty acids in <i>Mycobacterium leprae</i> . Kusaka, T. and Izumi, S. (A)	624
Generation and characterization of monoclonal antibodies to the <i>Mycobacterium leprae</i> phenolic glycolipid. Khanolkar, S. R., <i>et al.</i> (A)	662
IgA, IgM and IgG anti- <i>M. leprae</i> antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., <i>et al.</i> (A)	136
IgE in leprosy; effect of a <i>Mycobacterium leprae</i> -BCG vaccine. LYNCH, N. R., <i>et al.</i> (O)	169
<i>In vitro</i> cultivation of <i>Mycobacterium X</i> from <i>Mycobacterium leprae</i> -infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. (O)	77
<i>In vitro</i> proliferative response to <i>M. leprae</i> and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., <i>et al.</i> (A)	442
Infection of the congenitally athymic rat with <i>Mycobacterium leprae</i> . DAWSON, P. J., <i>et al.</i> (O)	336
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from <i>Mycobacterium lufu</i> and <i>Mycobacterium leprae</i> . A comparison. Kulkarni, V. M. and Seydel, J. K. (A)	274
Isolation of a characteristic phthiocerol dimycocerosate from <i>Mycobacterium leprae</i> . Draper, P., <i>et al.</i> (A)	446
Lack of correlation between morphological index and viability as assessed by the uptake of ³ H-thymidine by macrophage resident <i>M. leprae</i> . Sathish, M., <i>et al.</i> (A)	142
Leprosy review: The bacteriology of <i>Mycobacterium leprae</i> . DRAPER, P. (O)	563
Lymphocyte subpopulations in mice infected with <i>Mycobacterium leprae</i> . Ganguly, N. K., <i>et al.</i> (A)	450
Metabolism of carbon sources of <i>Mycobacterium leprae</i> : a preliminary report. Wheeler, P. R. (A)	143
Method of cultivation of <i>M. leprae</i> . Veeraraghavan, N. (A)	291
Modification of the kinetics of growth of <i>Mycobacterium leprae</i> by a group of corynebacteria. Delville, J., <i>et al.</i> (A)	290
Mouse foot pad technique for evaluation of drug resistance of <i>M. leprae</i> and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. (A)	436

- Mouse foot-pad growth patterns of *M. leprae* in relation to Morphological Index. Venkataramaniah, H. N., *et al.* (A) 295
- Mycobacterium leprae* infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* (A) 293
- N-Acetyl- β -glucosaminidase, β -glucuronidase and acid phosphatase in *Mycobacterium leprae*. Wheeler, P. R., *et al.* (A) 291
- Persistence of *Mycobacterium leprae* in the peripheral nerve. Antia, M. H. and Nedugayil, K. (A) 615
- Progress in the preparation of an antileprosy vaccine from armadillo-derived *Mycobacterium leprae*. REES, R. J. W. (O) 515
- Prospects for a *Mycobacterium leprae* vaccine against leprosy after Madras. Stoner, G. L. (A) 645
- Pyrolysis mass spectrometry: its applicability to mycobacteriology, including *Mycobacterium leprae*. Wieten, G., *et al.* (A) 448
- Radiolabelled *M. leprae* resident in human macrophage cultures as an *in vitro* indicator of effective immunity in human leprosy. Prasad, H. K., *et al.* (A) 137
- Rapid, radiolabeled-microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibility. Mittal, A., *et al.* (A) 446
- Reduction of potassium tellurite and ATP content in *Mycobacterium leprae*. David, H. L., *et al.* (A) 445
- Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., *et al.* (O) 305
- Replication of *Mycobacterium leprae* in hibernating ground squirrels (*Citellus tridecemlineatus*). Galletti, G., *et al.* (A) 143
- Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* (A) 610
- Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* ... (A) 649
- Ribosomal antigens of *Mycobacterium leprae*. Ridell, M. (A) 291
- SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* (A) 134
- Sensitization or tolerance to *Mycobacterium leprae* antigen by route of injection. Shepard, C. C., *et al.* (A) 138
- Serodiagnosis of infection with *Mycobacterium leprae*. BUCHANAN, T. M., *et al.* (O) 524
- Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. Cho, S.-N., *et al.* (A) 616
- Serological specificity of phenolic glycolipid-I from *Mycobacterium leprae* and use of serodiagnosis in leprosy. Cho, S.-N., *et al.* (A) 659
- Studies on sulphone resistant strains of *M. leprae* in field and institutionalized cases of leprosy. Balakrishnan, S., *et al.* (A) 436
- Survival of *Mycobacterium leprae* in mice administered several antibiotics *per os*. LEVY, L., *et al.* (C) 254
- Taxonomic studies on *Mycobacterium leprae*. Dhople, A. M. (A) 446
- Taxonomy of *Mycobacterium leprae* and *M. lepraemurium*. Portaels, F. and Pattyn, S. R. (A) 447
- The degradation of *Mycobacterium leprae* by a comparison of its staining properties. RIDLEY, M. J. (O) 211
- The distribution of *Mycobacterium leprae* in the hair follicle of the eyebrow. GUMMER, C. L., *et al.* (O) 205
- The mycolic acids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Draper, P., *et al.* (A) 446
- The phthiocerol-containing surface lipids of *Mycobacterium leprae*—a perspective of past and present work. BRENNAN, P. J. (E) 387
- The production of human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T. and Roder, J. C. (A) 656
- The significance of dapsone (DDS)-resistant *Mycobacterium leprae* in untreated patients. ALMEIDA, J. G., *et al.* (O) 374

Ultrastructural alterations of <i>Mycobacterium leprae</i> in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., <i>et al.</i> (A)	291
Ultrastructure of <i>Mycobacterium leprae</i> and other acid-fast bacteria as influenced by fixation conditions. Silva, M. T. and Macedo, P. M. (A)	448
Use of a unit gravity sedimentation chamber for the purification of <i>Mycobacterium leprae</i> . Das, P. K. and Tulp, A. (A)	289
Variable lepromin response to <i>Mycobacterium leprae</i> in resistant armadillos. Job, C. K., <i>et al.</i> (O)	347
<i>Mycobacterium lepraemurium</i>,	
Biochemical properties of <i>Mycobacterium lepraemurium</i> cultivated in cell-free liquid medium. Nakamura, M. (A)	654
Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of <i>Mycobacterium lepraemurium</i> TMC 1701. Katoch, V. M., <i>et al.</i> (A)	290
Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., <i>et al.</i> (A)	293
Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in <i>Mycobacterium lepraemurium</i> infection. Hoffenbach, A., <i>et al.</i> (A)	292
Deoxyribonucleic acid of <i>Mycobacterium lepraemurium</i> : Its genome size, base ratio, and homology with those of other bacteria. Imaeda, T., <i>et al.</i> (A)	290
Effect of phorbol myristate acetate, a tumor-promoting agent, on the growth of <i>Mycobacterium lepraemurium</i> in the mouse footpad. Tomioka, H. and Saito, H. (A)	626
Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. HIRATA, T. (O)	84
Enhanced growth of <i>Mycobacterium lepraemurium</i> in cell-free liquid medium with DL-aspartic acid. Nakamura, M. (A)	290
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)	294
Evidence for generation of suppressor T cells in <i>Mycobacterium lepraemurium</i> -infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hirooka, Y. (A)	450
Growth stimulation of <i>Mycobacterium lepraemurium</i> by liposome in cell-free liquid medium. Nakamura, M. (A)	141
H-2 linkage control of resistance to subcutaneous infection with <i>Mycobacterium lepraemurium</i> . Curtis, J., <i>et al.</i> (A)	143
<i>In vitro</i> sensitivity of <i>Mycobacterium lepraemurium</i> for antimycobacterial drugs. Portaels, F., <i>et al.</i> (A)	142
Inbred mouse strain resistance to <i>Mycobacterium lepraemurium</i> follows the <i>Ity/Lsh</i> pattern. Brown, I. N., <i>et al.</i> (A)	143
Increased H ₂ O ₂ production by splenic murine macrophages associated with susceptibility of <i>Mycobacterium lepraemurium</i> infection. Sankaran, K., <i>et al.</i> (A)	652
Induction of delayed type hypersensitivity against ultrasonicated <i>Mycobacterium lepraemurium</i> bacilli without simultaneous local reactivity against live bacilli. Lovik, M. and Closs, O. (A)	625
Macrophage function in <i>Mycobacterium lepraemurium</i> infection: Morphological and functional changes of peritoneal and splenic macrophages <i>in vitro</i> . Ha, D. K. K., <i>et al.</i> (A)	292
Metabolism of glycerolipids in <i>Mycobacterium lepraemurium</i> ; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. (A)	653
Morphology of bacteriophages from <i>Mycobacterium lepraemurium</i> . Rastogi, N. and David, H. L. (A)	142
Observations on the host reaction to the cultivated <i>Mycobacterium lepraemurium</i> in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. (A)	294
Pathogenicity of <i>in vitro</i> cultivated <i>Mycobacterium lepraemurium</i> in rats. Ishaque, M. (A)	293
Peripheral neuropathy in mice infected with <i>Mycobacterium lepraemurium</i> . Lefford, M. J., <i>et al.</i> (A)	651

- Respiratory activities of *in vitro* grown *Mycobacterium lepraemurium*. ISHAQUE, M. (O) 64
- Role of the major histocompatibility complex in resistance and granuloma formation in response to *Mycobacterium lepraemurium* infection. Adu, H. O., *et al.* (A) 441
- Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium lepraemurium* in cell-free liquid medium. Nakamura, M. (A) 141
- Stimulation effect of dextran on *in vitro* growth of *Mycobacterium lepraemurium*. Nakamura, M. (A) 290
- Study of growth factor for *Mycobacterium lepraemurium* grown in the Ogawa yolk medium. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M.-M. (A) 141
- Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* (A) 625
- Taxonomy of *Mycobacterium leprae* and *M. lepraemurium*. Portaels, F. and Pattyn, S. R. (A) 447
- The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium*. Adu, H. O., *et al.* (A) 449
- The microcolonial texture and demonstration of a phage-like lysis in the "Douglas" strain of *Mycobacterium lepraemurium*. Sula, L. (A) 448
- The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* (A) 625
- Use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. MATSUO, Y. (O) 72
- Mycobacterium lufu*,**
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. (A) 274
- Mycobacterium smegmatis*,**
Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* (A) 443
- Mycobacterium tuberculosis*,**
Bacteriophage typing of strains of *Mycobacterium tuberculosis* from Nepal. Goode, D. (A) 299
- Characterization of a suppressor cell-activating factor (SCAF) released by adherent cells treated with *M. tuberculosis*. Wadee, A. A., *et al.* (A) 444
- Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* (A) 155
- Isolation and study of the morphological properties and immunogenicity of *Mycobacterium tuberculosis*. Khomenko, A. G., *et al.* (A) 633
- Mycobacterium w*,**
Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved *Mycobacterium w*. CHAUDHURI, S., *et al.* (O) 159
- Mycobacterium X*,**
In vitro cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. (O) 77
- Near East,**
Diffuse lepromatosis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. (A) 281
- Neck,**
Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. (A) 276
- Necrolysis,**
Toxic epidermal necrolysis (Lyell syndrome). Katoch, K., *et al.* (A) 437

Nepal,

- Bacteriophage typing of strains of *Mycobacterium tuberculosis* from Nepal. Goode, D. (A) 299
 Tuberculosis case-finding in eastern Nepal. Cassels, A., *et al.* (A) 154

Nerve(s),

- A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, *et al.* (A) 135
 Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, *et al.* (A) 135
 Assessment of cutaneous autonomic nerve functions in leprosy. Boyle, A. and Ramu, G. (A) 151
 Calcification in ulnar nerve abscess in a patient with leprosy—a case report. Prasad, S. B. (A) 280
 Clinical, electrophysiological and teased fibre study of peripheral nerves in leprosy. Chopra, J. S., *et al.* (A) 631
 Functional changes of the ulnar nerve in leprosy patients following neurolysis. Brandsma, J. W., *et al.* (A) 298
 Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., *et al.* (A) 280
 Nerve conduction in leprosy: *in vivo* and *in vitro* study. Donde, S. V., *et al.* (A) 440
 Persistence of *Mycobacterium leprae* in the peripheral nerve. Antia, M. H. and Nedugayil, K. (A) 615
 Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., *et al.* (A) 277
 Quantitative analysis of the sequence of nerve damage in experimental leprosy. Bhat, K. R. and Vaidya, M. C. (A) 292
 Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., *et al.* (A) 153
 Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. (A) 449

Netherlands, The,

- INFOLEP 1982 Annual Report. (N) 603
 The development of clinical tuberculosis following infection with tubercule bacilli. I. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., *et al.* (A) 302

Neurology,

- 1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky, C. B. (A) 151
 Immune responses to bovine neural antigens in leprosy patients. I. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., *et al.* (O) 33
 Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., *et al.* (A) 277

Neuritis,

- Reproducibility of sensory testing and voluntary muscle testing in evaluating the treatment of acute neuritis in leprosy patients. Lewis, S. (A) 279

Neuropathy,

- Autonomic neuropathy in leprosy. KYRIAKIDIS, M. K., *et al.* (O) 301
 Neuropathies in Hansen's disease. CHAROSKY, C. B., *et al.* (E) 576
 Peripheral neuropathy in mice infected with *Mycobacterium lepraemurium*. Lefford, M. J., *et al.* (A) 651

Nose,

- Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., *et al.* (O) 22
 "Jal Neti" a yoga technique for nasal comfort and hygiene in leprosy patients. Appa Rao, A. V. N., *et al.* (A) 275

Obituaries (see also under surnames),

- Belehu, Ayele. Haregewoin, A. and Olcen, P. (Ob) 404
 Davey, Thomas Frank. Seal, K. S. (Ob) 405

Fieldsteel, A. Howard. Dawson, P. J. and Krahenbuhl, J. L. (Ob)	105
Guinto, Ricardo S. Binford, C. H. and Reich, C. V. (Ob)	587
Ross, Sister Hilary. (Ob)	253
Okinawa,	
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. (A)	296
OMSLEP,	
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. (B)	608
Orchiepididymitis,	
Orchiepididymitis in dimorphous leprosy. Gimenez, M. F. and Tonelli, H. B. (A)	278
Osteosclerosis,	
Osteosclerosis in leprosy. Simone, C. and Racanelli, A. (A)	615
Otolaryngology,	
Otolaryngologic manifestations of Hansen's disease. Stevens, M. H. and Nielsen, D. R. (A)	615
Papua New Guinea,	
Hepatic structure and function in Papua New Guineans with leprosy. Cook, G. C. and Corachan, M. (A)	276
The treatment of leprosy in Papua New Guinea. Ree, G. H. (A)	438
Paramedics,	
<i>Teaching Guide for Paramedical Workers in Leprosy.</i> Vol. 2. Chaudhury, D. S. (B)	126
Pathology,	
Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, <i>et al.</i> (A)	135
Adherence of <i>Mycobacterium leprae</i> to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. (A)	284
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. (A)	139
Pathogenicity of <i>in vitro</i> cultivated <i>Mycobacterium lepraemurium</i> in rats. Ishaque, M. (A)	293
"Pro-eukaryote" graft acceptance: A mechanism for intracellular parasitism—a new hypothesis for pathogenesis of leprosy. Deo, M. G. (A)	617
Pediatrics,	
Leprosy—a major community health problem in pediatric age group. Das, M. L., <i>et al.</i> (A)	295
Phagocytosis,	
Phagocytosis and lysis of <i>Candida albicans</i> and <i>Candida pseudotropicalis</i> by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., <i>et al.</i> (A)	283
Phagocytosis of <i>Candida albicans</i> by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., <i>et al.</i> (A)	287
Phenolic glycolipid(s),	
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of <i>Mycobacterium leprae</i> . Young, D. B. and Buchanan, T. M. (A)	660
Evaluation of the significance of antibodies to phenolic glycolipid of <i>Mycobacterium leprae</i> in leprosy patients and their contacts. Buchanan, T. M., <i>et al.</i> (A)	658
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from <i>Mycobacterium leprae</i> . Hunter, S. W. and Brennan, P. J. (A)	623
Generation and characterization of monoclonal antibodies to the <i>Mycobacterium leprae</i> phenolic glycolipid. Khanolkar, S. R., <i>et al.</i> (A)	662
Serological specificity of phenolic glycolipid I from <i>Mycobacterium leprae</i> and use in serodiagnosis of leprosy. Cho, S.-N., <i>et al.</i> (A)	616

Serological specificity of phenolic glycolipid-I from <i>Mycobacterium leprae</i> and use of serodiagnosis in leprosy. Cho, S.-N., <i>et al.</i> (A)	659
Phenotypes,	
Erythrocyte glucose-6-phosphate dehydrogenase isoenzyme phenotypes in leprosy. SAO-JI, A. M. and KELKAR, S. S. (O)	41
The cutaneous infiltrates of leprosy. Cellular characteristics and the predominant T cell phenotypes. Van Voorhis, W. C., <i>et al.</i> (A)	288
Philippines, The,	
Dr. Jose Tolentino succumbs. Binford, C. H. (N)	429
Phorbol myristate acetate,	
Effect of phorbol myristate acetate, a tumor-promoting agent, on the growth of <i>Mycobacterium lepraemurium</i> in the mouse footpad. Tomioka, H. and Saito, H. (A)	626
6-Phosphogluconate,	
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in <i>Mycobacterium leprae</i> grown in armadillo tissues. Wheeler, P. R. (A)	624
Phospholipid(s),	
Metabolism of glycerolipids in <i>Mycobacterium lepraemurium</i> ; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. (A)	653
Phthiocerol,	
Isolation of a characteristic phthiocerol dimycocerosate from <i>Mycobacterium leprae</i> . Draper, P., <i>et al.</i> (A)	446
The phthiocerol-containing surface lipids of <i>Mycobacterium leprae</i> —a perspective of past and present work. BRENNAN, P. J. (E)	387
Physiotherapy,	
Physiotherapy in leprosy. Furness, M. A. (A)	271
Polysaccharide(s),	
Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., <i>et al.</i> (A)	139
Structure of the wall polysaccharide isolated from a group of corynebacteria. Abou-Zeid, C., <i>et al.</i> (A)	622
Protease,	
Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., <i>et al.</i> (A)	441
Protein(s),	
Immune responses to bovine neural antigens in leprosy patients. I. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., <i>et al.</i> (O)	33
SDS-PAGE analysis of <i>M. leprae</i> protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., <i>et al.</i> (A)	134
Serological study of presence of C-reactive protein, rheumatoid factor, anti-streptolysin O in leprosy cases. Bhatia, V. N., <i>et al.</i> (A)	439
Study of growth factor for <i>Mycobacterium lepraemurium</i> grown in the Ogawa yolk medium. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M.-M. (A)	141
Prothionamide,	
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., <i>et al.</i> (C)	592
Disposition of prothionamide in rats and armadillos. PETERS, J. H., <i>et al.</i> (O)	54
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., <i>et al.</i> (O)	461
Prurigo nodularis,	
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. BELAUBE, P., <i>et al.</i> (O)	328

Psoriasis,

- Increased helper-suppressor T cell ratio in psoriasis. Ligesti, D. J., *et al.* (A) 155

Purified protein derivative (PPD),

- Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. (A) 299
- Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* (A) 285
- In vitro* proliferative response to *M. leprae* and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., *et al.* (A) 442

Radiology,

- Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* (A) 279
- Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* (A) 630

Rat(s),

- Disposition of prothionamide in rats and armadillos. PETERS, J. H., *et al.* (O) 54
- Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* (A) 620
- Infection of the congenitally athymic rat with *Mycobacterium leprae*. DAWSON, P. J., *et al.* (O) 336
- Pathogenicity of *in vitro* cultivated *Mycobacterium lepraemurium* in rats. Ishaque, M. (A) 293
- The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* (A) 621

Reaction(s),

- A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. (A) 273
- A comparison of the incidence of type 2 reactions in lepromatous leprosy with two regimens of treatment. Manungo, J. and Thomas, J. E. P. (A) 130
- A study of type 2 reactions in lepromatous leprosy. Manungo, J. and Thomas, J. E. P. (A) 131
- Alpha-1-antitrypsin in lepra reaction. Chawhan, R. N., *et al.* (A) 614
- Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* (A) 293
- Evolutionary aspects of the Rubino reaction. Opromolla, D. V. A., *et al.* (A) 287
- In situ* characterization of T lymphocyte subsets in the reactional states of leprosy. Modlin, R. L., *et al.* (A) 619
- Leprosy downgrading reaction associated with griseofulvin. Shulman, D. G., *et al.* (A) 132
- Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. (A) 294
- Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., *et al.* (A) 613
- Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., *et al.* (A) 441
- Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* (O) 466
- Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* (A) 649
- Sequential histological study of lepromin reaction. DESIKAN, K. V., *et al.* (O) 473
- Simultaneous type I and type II reactions. CLEZY, J. K. A. (C) 413
- The reversal or inversal reaction—present point. Carayon, A. (A) 130
- Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* (A) 647

Refugees,		
Leprosy in Vietnamese refugees: a case report. Christiansen, J. V., <i>et al.</i> (A)		276
Leprosy; our Southeast Asian refugee experience. Younger, B., <i>et al.</i> (A)		150
Rehabilitation,		
Contribution of surgery to the treatment and rehabilitation of patients with leprosy.		
Bourrel, P. (A)		630
Rehabilitation of leprosy deformity. Enna, C. D. (A)		152
Rheumatoid factor,		
Serological study of presence of C-reactive protein, rheumatoid factor, anti-streptolysin O in leprosy cases. Bhatia, V. N., <i>et al.</i> (A)		439
Rhinoscleroma,		
<i>In situ</i> demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., <i>et al.</i> (A)		285
Rifampin,		
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., <i>et al.</i> (C)		592
Eosinophilia as a result of rifampicin therapy. Nigam, P., <i>et al.</i> (A)		131
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., <i>et al.</i> (O)		461
<i>In vitro</i> activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against <i>Mycobacterium avium-intracellulare</i> complex. Zimmer, B. L., <i>et al.</i> (A)		157
Resistance of <i>Mycobacterium leprae</i> to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., <i>et al.</i> (A)		610
Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., <i>et al.</i> (A)		129
Therapeutic study in leprosy. VI. Observation of the therapeutic effect of isobutylpiperazinylrifamycin. Shanghai Zhunyi Hospital, <i>et al.</i> (A)		611
Unique and high doses of rifampin in leprosy treatment. A warning. Pattyn, S. R., <i>et al.</i> (A)		610
Ross, Sister Hilary,		
Obituary (Ob)		253
Rubino reaction,		
Evolutionary aspects of the Rubino reaction. Opromolla, D. V. A., <i>et al.</i> (A)		287
Saliva,		
Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., <i>et al.</i> (O)		22
Salivary immunoglobulin and antibody activities in leprosy. Abe, M., <i>et al.</i> (A)		657
Sarcoidosis,		
Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. (A)		632
<i>In situ</i> demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., <i>et al.</i> (A)		285
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., <i>et al.</i> (A)		632
Screening for leprosy,		
Development of an enzyme-linked immunosorbent assay using arabinomannan from <i>Mycobacterium smegmatis</i> : A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., <i>et al.</i> (A)		443
Rapid screening for leprosy. Caver, C. V. (A)		613
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A)		157
SEARO,		
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18-19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14-16 February 1983. (O)		500

Sensation(s),		
Congenital absence of sensation. Krishnamoorthy, K. V. (A)		131
Plantar trophic ulcers in patients with leprosy. A correlative study of sensation, pressure and mobility. Sabato, S., <i>et al.</i> (A)		631
Sensitivity,		
Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. PETTIT, J. H. S. (C)		258
Corticosteroids and lepromin sensitivity. Kundu, S. K., <i>et al.</i> (A)		131
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)		294
<i>In vitro</i> sensitivity of <i>Mycobacterium lepraemurium</i> for antimycobacterial drugs. Portaels, F., <i>et al.</i> (A)		142
Sensitivity of mycobacteria to dapsone. Portaels, F., <i>et al.</i> (A)		142
Sera, of leprosy patients,		
Creatinphosphokinase (CPK) activity in the sera of hanseniasis patients. Garcia, R. R., <i>et al.</i> (A)		277
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., <i>et al.</i> (A)		442
SDS-PAGE analysis of <i>M. leprae</i> protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., <i>et al.</i> (A)		134
Serodiagnosis,		
Serodiagnosis of infection with <i>Mycobacterium leprae</i> . BUCHANAN, T. M., <i>et al.</i> (O)		524
Serodiagnosis of leprosy: the past, the present, and some prospects for the future. MEL-SOM, R. (E)		235
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A)		157
Serological specificity of phenolic glycolipid I from <i>Mycobacterium leprae</i> and use in serodiagnosis of leprosy. Cho, S.-N., <i>et al.</i> (A)		616
Serological specificity of phenolic glycolipid-I from <i>Mycobacterium leprae</i> and use of serodiagnosis in leprosy. Cho, S.-N., <i>et al.</i> (A)		659
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shrinivas. (A)		154
Serum,		
A study of serum fibrinolytic activity in erythema nodosum leprosum (ENL). Jain, V. K., <i>et al.</i> (A)		440
Concentration of serum calcium in leprosy. Pal, R., <i>et al.</i> (A)		441
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., <i>et al.</i> (A)		132
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. Wu Qin-xue. (N)		119
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., <i>et al.</i> (A)		443
Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Hari-krishnan, S., <i>et al.</i> (A)		134
Serum levels of C3-activator (antifactor B) in leprosy. WEMAMBU, S. N. C. (C)		259
Serum lipoproteins in lepromatous leprosy. Kher, J. R., <i>et al.</i> (A)		441
Serum macrophage migration inhibition activity in patients with leprosy. Rea, T. H. and Yoshida, T. (A)		288
Serum-mediated suppression of E-RFC levels in leprosy and reversal by fetal calf serum. Jaswaney, V. L., <i>et al.</i> (A)		284
Shoe(s),		
Simple plantar ulcers treated by below-knee plaster and moulded double-rocker plaster shoe—a comparative study. Pring, D. J. and Casabianca, N. (A)		153
The moulded double-rocker plaster shoe in the field treatment of plantar ulcer. Joseph, B., <i>et al.</i> (A)		298

Skin,		
Composite skin contact smears in multibacillary leprosy patients. Hameedullah, A., <i>et al.</i> (A)		278
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schieffer, H. B. and Middleton, D. M. (A)		626
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed <i>Mycobacterium leprae</i> : Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., <i>et al.</i> (O)		481
Immunoglobulin deposits in leprosy skin. Higashi, G. I., <i>et al.</i> (A)		440
Immunohistological studies of skin biopsies from patients with lepromatous leprosy. Mshana, R. N., <i>et al.</i> (A)		286
Skin diseases in Addis Ababa: A preliminary review. Manzur, J. (A)		279
T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., <i>et al.</i> (A)		274
The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., <i>et al.</i> (A)		621
Ultrastructural alterations of <i>Mycobacterium leprae</i> in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., <i>et al.</i> (A)		291
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., <i>et al.</i> (A)		442
Skin tests,		
The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Nye, P. M., <i>et al.</i> (A)		287
Somalia,		
Remarks on the orofacial symptoms of leprosy observed in Somalia. Goracci, G. and Clangelo, G. (A)		614
Southeast Asia,		
Leprosy; our Southeast Asian refugee experience. Younger, B., <i>et al.</i> (A)		150
Spain,		
Fontilles announces courses in leprosy. (N)		266
Spectrometry,		
Pyrolysis mass spectrometry: its applicability to mycobacteriology, including <i>Mycobacterium leprae</i> . Wieten, G., <i>et al.</i> (A)		448
Spleen,		
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and <i>Mycobacterium lepraemurium</i> . Stach, J.-L., <i>et al.</i> (A)		294
Increased H ₂ O ₂ production by splenic murine macrophages associated with susceptibility of <i>Mycobacterium lepraemurium</i> infection. Sankaran, K., <i>et al.</i> (A)		652
Macrophage function in <i>Mycobacterium lepraemurium</i> infection: Morphological and functional changes of peritoneal and splenic macrophages <i>in vitro</i> . Ha, D. K. K., <i>et al.</i> (A)		292
Squirrel(s),		
Replication of <i>Mycobacterium leprae</i> in hibernating ground squirrels (<i>Citellus tridecemlineatus</i>). Galletti, G., <i>et al.</i> (A)		143
Stain(s),		
The degradation of <i>Mycobacterium leprae</i> by a comparison of its staining properties. RIDLEY, M. J. (O)		211
Steroid(s),		
Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., <i>et al.</i> (A)		153
Streptomycin,		
<i>In vitro</i> activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against <i>Mycobacterium avium-intracellulare</i> complex. Zimmer, B. L., <i>et al.</i> (A)		157

Sulfone(s),

- A simple urine test for sulfonamides. de Almeida-Filho, J. and de Souza, J. M. (A) 273
- Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—
comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L.
and Sanchez Caballero, H. (A) 131
- Glucose-6-phosphate dehydrogenase in Hansen's disease patients receiving sulfones or
sulfamethoxypyridazine. Takizawa, H., *et al.* (A) 281
- Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences
of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-
Lauras, C.-C., *et al.* (A) 610
- Studies on sulphone resistant strains of *M. leprae* in field and institutionalized cases of
leprosy. Balakrishnan, S., *et al.* (A) 436
- Treatment of sulphone resistant leprosy—a review of sixty one cases. Seshadri, P. S.
and Ravi, N. T. (A) 275

Surgery,

- 1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky,
C. B. (A) 151
- A comparative study of EFMT and sublimis transfer operations in the claw hand.
SUNDARARAJ, G. D., *et al.* (O) 197
- Contribution of surgery to the treatment and rehabilitation of patients with leprosy.
Bourrel, P. (A) 630
- Correction of cubital contractures in leprosy patient employing Zancolli's lasso tech-
nique. Boucher, P. (A) 630
- Correction of the paralytic claw-thumb by two-tailed transfer of the superficialis tendon
through a window in the flexor retinaculum. Srinivasan, H. (A) 153
- Timing of tendon-transfer surgery. Brandsma, J. W. and Liftogt, T. (A) 630
- Transposition of post-tibial muscles and fasciae for correcting leprosy patient's drop
foot. Lin De-Pao, *et al.* (A) 298

Surinam,

- HLA-DR-associated genetic control of the type of leprosy in a population from Surinam.
van Eden, W., *et al.* (A) 150

Switzerland,

- IMMLEP and THELEP seek trial sites. (N) 604
- Report of the 11th and 12th meetings of the Steering Committee of the Scientific Working
Group on the Chemotherapy of Leprosy. (N) 429
- Sixth report of the WHO Special Programme for Research and Training in Tropical
Diseases. (N) 604

Synovitis,

- Leprous synovitis. A study of fifty cases. HOLLA, V. V., *et al.* (O) 29

Syphilis,

- Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-
related antigen in syphilis and leprosy. Morito, T., *et al.* (A) 619

Tape,

- Treatment of leprosy wounds with adhesive zinc tape. Soderberg, T., *et al.* (A) 153

Thailand,

- German Leprosy Relief Association funds leprosy work. (N) 605
- Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia,
Bangkok, Thailand, 18–28 January 1982. (B) 607

Thalidomide,

- A comparative study between the therapeutic activity of thalidomide and the therapeutic
activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis.
Almeida Neto, E. (A) 273
- Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. (A) 632
- Thalidomide: a review of the literature. Santos, M. F. G., Jr., *et al.* (A) 275
- Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with
thalidomide. Saint-André, P., *et al.* (A) 611

THELEP,

- IMMLEP and THELEP seek trial sites. (N) 604
- Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. (O) 500

Therapy,

- Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* (O) 191
- Eosinophilia as a result of rifampicin therapy. Nigam, P., *et al.* (A) 131
- Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. (A) 438
- Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., *et al.* (A) 153
- Treatment of leprosy using combination therapy—but how? FREERKSEN, E. (C) 407

Thymidine,

- Lack of correlation between morphological index and viability as assessed by the uptake of ³H-thymidine by macrophage resident *M. leprae*. Sathish, M., *et al.* (A) 142

Thymus,

- Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., *et al.* (A) 286

Tissue(s),

- Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. (A) 624
- Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* (A) 290
- Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* (A) 293
- Effect of freezing *Mycobacterium leprae* in tissues. Dhople, A. M. (A) 140
- In vitro* cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. (O) 77
- Mycobacterial lipids in infected tissue samples. Young, D. B. (A) 292
- Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. (A) 294
- Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. (A) 157
- Serological approaches for the characterization of catalase in tissue-derived mycobacteria. Katoch, V. M., *et al.* (A) 624
- The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium*. Adu, H. O., *et al.* (A) 449
- Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* (A) 647

Tongue,

- Atrophic lesions of the tongue in leprosy patients. Prabhu, S. R. and Daftary, D. K. ... (A) 280

Toxicity,

- Toxic epidermal necrolysis (Lyell syndrome). Katoch, K., *et al.* (A) 437

Training,

- Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia, Bangkok, Thailand, 18–28 January 1982. (B) 607
- Sixth report of the WHO Special Programme for Research and Training in Tropical Diseases. (N) 604
- The Social Dimension of Leprosy. Training Manual for Health Workers.* Kaufmann, A., *et al.* (B) 270

Trial(s),

- Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. (O) 556

IMMLEP and THELEP seek trial sites. (N)	604
Management of clinical trials in developing countries. de Maar, E. W. J., <i>et al.</i> (A)	277
Methodology of therapeutic trials in leprosy. Ji Bao-Hong. (A)	273
Operational problems in vaccine trials. GULD, J. (O)	559
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. (A)	438
Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., <i>et al.</i> (A)	129
Solid, fragmented and granular index as one of the parameters in drug trials. Sharma, V. D., <i>et al.</i> (A)	132
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. (A)	296
Tuberculin,	
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., <i>et al.</i> (A)	302
Antigens of PPD, old tuberculin, and autoclaved <i>Mycobacterium bovis</i> BCG studied by crossed immunoelectrophoresis. Harboe, M. (A)	299
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., <i>et al.</i> (A)	300
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. (A)	300
Tuberculoid leprosy,	
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, <i>et al.</i> (A)	135
An approach to study <i>in vitro</i> the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., <i>et al.</i> (A)	444
Effect of treatment on antibody activity against <i>Mycobacterium leprae</i> antigen 7 in tuberculoid leprosy. DAHLE, J. S., <i>et al.</i> (O)	312
Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., <i>et al.</i> (A)	285
<i>In vitro</i> lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. (C)	110
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., <i>et al.</i> (A)	613
Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., <i>et al.</i> (A)	277
Relation between anti- <i>Mycobacterium leprae</i> antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., <i>et al.</i> (O)	305
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., <i>et al.</i> (A)	650
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. (A)	137
Tuberculosis,	
Active and total E-rosette forming T-lymphocytes in pulmonary tuberculosis. Prabhu, R. and Reddy, M. V. (A)	634
Activity of amikacin against mycobacteria <i>in vitro</i> and in murine tuberculosis. Sanders, W. E., Jr., <i>et al.</i> (A)	156
Amikacin in the treatment of pulmonary tuberculosis. Allen, B. W., <i>et al.</i> (A)	631
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., <i>et al.</i> (A)	302
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., <i>et al.</i> (A)	279
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., <i>et al.</i> (A)	300
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences	

in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. (A)	300
Immunity in tuberculosis. Chaparas, S. D. (A)	154
Immunological research in tuberculosis: Memorandum from a WHO meeting. (A)	299
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. (A)	139
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shrinivas. (A)	154
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., <i>et al.</i> (A)	302
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., <i>et al.</i> (A)	133
Tuberculosis and leprosy control: WHO consultation. (A)	451
Tuberculosis case-finding in eastern Nepal. Cassels, A., <i>et al.</i> (A)	154
Tuberculosis in India—the prospect. Sivaraman, S. (A)	635
Ultrastructural characteristics,	
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. (A)	621
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. (O)	225
Ultrastructural alterations of <i>Mycobacterium leprae</i> in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., <i>et al.</i> (A)	291
Ultrastructure of <i>Mycobacterium leprae</i> and other acid-fast bacteria as influenced by fixation conditions. Silva, M. T. and Macedo, P. M. (A)	448
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., <i>et al.</i> (A)	442
Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. (A)	449
Uremia,	
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., <i>et al.</i> (A)	443
Urine,	
A simple urine test for sulfonamides. de Almeida-Filho, J. and de Souza, J. M. (A)	273
Immunoglobulins in the urine of leprosy patients. SENGUPTA, U., <i>et al.</i> (C)	409
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China). Wu Qin-xue. (N)	119
U.S.A.,	
Carville Director appointed Acting Division Director. (N)	123
Damien-Dutton Society history. Crouch, H. E. (N)	124
Dr. Roy F. Pfaltzgraff joins American Leprosy Missions. (N)	124
Eighteenth Joint Leprosy Conference, Bethesda, Maryland, U.S.A., 3–4 August 1983. (U.S.–Japan Cooperative Medical Science Program) (–)	636
Hansen's disease in the United States. Hudson, T. and Genessi, J. (A)	295
Leonard Wood Memorial research grant for early diagnosis of leprosy. (N)	605
Leprosy cases reported in the United States in 1982. (N)	124
Leprosy in wild armadillos (<i>Dasypus novemcinctus</i>) of the Texas Gulf Coast: Epidemiology and mycobacteriology. Smith, J. H., <i>et al.</i> (A)	629
President Ronald Reagan joins in observing World Leprosy Day. (N)	124
Sylvatic leprosy in wild armadillos of the Texas Gulf Coast. Smith, J. H., <i>et al.</i> (A)	663
Waldemar F. Kirchheimer, M.D., Ph.D., retires from National Hansen's Disease Center. Hastings, R. C. (N)	124
U.S.–Japan Cooperative Medical Science Program,	
Eighteenth Joint Leprosy Conference, Bethesda, Maryland, U.S.A., 3–4 August 1983. (U.S.–Japan Cooperative Medical Science Program) (–)	636

Vaccination,

- A model of vaccination with two microorganisms in infectious disease. Convit, J., *et al.* (A) 670
- Animal vaccination studies with *Mycobacterium leprae*. SHEPARD, C. C. (O) 519
- Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* (A) 301
- Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. (A) 633
- Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* (A) 300
- Effects of vaccination with *Mycobacterium leprae* on local cell-mediated immunity. Ridet, P.-R., *et al.* (A) 645
- Intradermal BCG vaccination complications—analysis of 51 cases. Murzy de Souza, G. R., *et al.* (A) 301
- Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. (A) 139
- Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. (A) 296
- The "Hansen-anergic fringe" and renewed doubts about vaccination. ROTBERG, A. (C) 411

Vaccine(s),

- Analyzing the cost-effectiveness and cost-benefit of vaccines. Sisk, J. E. and Sanders, C. R. (A) 634
- Antileprosy potentials of ICRC vaccine. A study in patients and healthy volunteers. DEO, M. G., *et al.* (O) 540
- Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae*, and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* (A) 626
- Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. (O) 556
- IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* (O) 169
- Investigations related to the development of a leprosy vaccine. CONVIT, J., *et al.* (O) 531
- Leprosy vaccines. BARKSDALE, L. (C) 107
- Natural history of leprosy—Aspects relevant to a leprosy vaccine. FINE, P. E. M. (O) 553
- Operational problems in vaccine trials. GULD, J. (O) 559
- Progress in the preparation of an antileprosy vaccine from armadillo-derived *Mycobacterium leprae*. REES, R. J. W. (O) 515
- Prospects for a *Mycobacterium leprae* vaccine against leprosy after Madras. Stoner, G. L. (A) 645
- Rationales for vaccines against leprosy. BLOOM, B. R. (O) 505
- Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* (O) 466
- Two candidate antileprosy vaccines—Current status of their development. TALWAR, G. P. and FOTEDAR, A. (O) 550

Vascular,

- Meningoencephalitis due to *Cryptococcus neoformans* complicated by arteriosclerotic vascular insufficiency in virchowian hanseniasis. Fleury, R. N., *et al.* (A) 277
- Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. (A) 449

Vasculitis,

- Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. (A) 633

Veins,

- Involvement of subcutaneous veins in lepromatous leprosy. MUKHERJEE, A., *et al.* (O) 1

Vietnam,

- Leprosy in Vietnamese refugees: a case report. Christiansen, J. V., *et al.* (A) 276

West Indies,

- Leprosy control project funded. (N) 432

World Health Organization (WHO),

- Immunological research in tuberculosis: Memorandum from a WHO meeting. (A) 299
- Sixth report of the WHO Special Programme for Research and Training in Tropical Diseases. (N) 604
- The WHO leprosy programme. Sansarricq, H. (A) 128
- Tuberculosis and leprosy control: WHO consultation. (A) 451

WPRO,

- Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. (O) 500

Zambia,

- National seminar on leprosy disability prevention. de Soldenhoff, R. (N) 125

Zimbabwe,

- Leprosy in Zimbabwe. Lyons, N. F. and Ellis, B. P. B. (A) 296
- Zimbabwe Leprosy Symposium. Browne, S. G. (N) 596

Zinc,

- Oral zinc in the trophic ulcers of leprosy. MATHUR, N. K. and BUMB, R. A. (C) 410
- Treatment of leprosy wounds with adhesive zinc tape. Soderberg, T., *et al.* (A) 153